



THE
REACTA FORUM
REACTA and TMU Clinical Trial Alliance International Conference



臺北醫學大學
TAIPEI MEDICAL UNIVERSITY

2021

FORUM REACTA

REACTA and TMU Clinical Trial
Alliance International Conference

PROGRAM BOOK



11/6 SAT

臺北醫學大學

醫學綜合大樓前棟4樓誠樸廳

www.reacta.com.tw

Regional Asian Clinical Trial Association

主辦單位：臺北醫學大學 人體研究處 | 臺北市立萬芳醫院 臺北醫學大學附設醫院 | 臺北醫學大學附設醫院 | 衛生福利部

協辦單位：臺北醫學大學 事業發展處、數據處 | EMUGLORIA | SPARK | BIOMEDACCELERATOR

指導單位：衛生福利部
Ministry of Health and Welfare

MOST 科技部
Ministry of Science and Technology

CONTENT

2021 REACTA Welcome Message	P.01
Acknowledgement	P.02
Agenda	P.03
CURRICURUM VITAE - David Lee	P.05
CURRICURUM VITAE - Hideki Hanaoka	P.07
CURRICURUM VITAE - OH, SUNG YONG	P.09
CURRICURUM VITAE - Audrey Ooi Joo Ann	P.12
CURRICURUM VITAE - Bannakij Lojanapiwat	P.15
CURRICURUM VITAE - Shian-Ying Sung	P.17
CURRICURUM VITAE - Katsumi Shigemura	P.20
CURRICURUM VITAE –Anthony Nguyen	P.51
CURRICURUM VITAE - Min-Huei (Marc) Hsu	P.53
CURRICURUM VITAE - CHUN (AUSTIN) CHANGOU	P.55
CURRICURUM VITAE - Shian-Ying Sung	P.61
CURRICURUM VITAE - Jowy Tani	P.64
CURRICURUM VITAE - Arthur Chen	P.66

2021 REACTA Welcome Message

Dear Colleagues and Friends,

Following the successful 2019 Regional Asian Clinical Trial Association (REACTA) Forum at Chiba University, we are proud to announce that the 2021 REACTA Forum will be held at Taipei Medical University **on November 6th, 2021**. I would like to express my sincere gratitude to all the international and domestic attendees for joining us.

REACTA Forum 2021 is the official forum of the Regional Asian Clinical Trial Association. Adopting a highly multidisciplinary approach. We aim at providing a rigorous review of the clinical trial management during the COVID-19 crisis and reports on the latest precision and translational clinical research findings as well as carry on the tradition of REACTA, which is making significant contributions and development in East Asia society.

This year, we will focus on clinical trial management, the emerging biomedical industry, and trials in drugs and medical devices. We are privileged to have renowned experts from Korea, Japan, Taiwan, Malaysia, and Thailand to share their knowledge and experiences with us. I believe this forum will provide an excellent opportunity for members and colleagues to stimulate and share the most up-to-date experiences and knowledge, especially during this pandemic.

Finally, I would like to thank all the friends and experts again for joining us. Looking forward to welcoming you all on November 6th, 2021.

Acknowledgement

The REACTA 2021 Organizing Committee would like to extend its great gratitude to the following international/local organizations and sponsors who generously contribute and support to the success of the REACTA 2021 in Taipei.

指導單位：

衛生福利部、科技部

主辦單位：

臺北醫學大學人體研究處

臺北醫學大學附設醫院

臺北市立萬芳醫院

衛生福利部雙和醫院

協辦單位：

1. 臺北醫學大學數據處、
2. 臺北醫學大學事業發展處。
3. 科技部科研產業化平台計畫
4. 科技部生醫與醫材轉譯加值人才培訓-ANCHOR UNIVERSITY 計畫
5. 科技部產業高階人才培訓計畫
6. 北醫生醫加速器計畫

Agenda

Time

Topic/Activity

REACTA and TMU Clinical Trial Alliance International Conference 2021

08:00 Registration

08:45 Welcome and Opening Ceremony
– Chien-Huang Lin (President, TMU)

09:00 Session 1 : The road to developing innovative and life-changing Medicine
– Lee, David JS (Novatis)

09:40 Discussion/ Break

Session 2 : Managing Clinical Trials By REACTA Members

09:50 What is necessary for ARO in Japan to overcome the COVID-19 crisis?
– Hideki Hanaoka / Chiba University Hospital, Japan

10:10 Clinical trial operation in Dong-A University Medical Center, South Korea
– Sung-Yong Oh / Dong-A University Medical Center, South Korea

10:30 The impact of the pandemic on sponsored research in Malaysia and the way forward
– Audrey Ooi / Clinical Research Malaysia (CRM), Malaysia

10:50 Clinical trial operation in Chiang Mai University, Thailand
– Bannakij Lojanapiwat / Chiang Mai University, Thailand

11:10 TMU as ARO to comprehensively enhance clinical trial services during the pandemic crisis
– Shian-Ying Sung / Taipei Medical University, Taiwan

11:30 Collaboration between TMU and Kobe University – Katsumi Shigemura, Japan

11:50 Discussion The future collaboration in REACTA members

12:10 Lunch Time

Agenda

Time	Topic/Activity
------	----------------

REACTA and TMU Clinical Trial Alliance International Conference 2021

Session 3 : The Organization from Bench to Business Development By TMU

13:00	The importance of collaboration and the future of the REACTA. – Anthony Va Nguyen / Dong-A University Hospital, South Korea
13:20	Collaboration with office of Data Science – Min-Huei Hsu
13:40	The Connection between bench and bedside: Core services in Taipei Medical University – Chun Austin Changou
13:50	TMU Biobank for the preclinical research, clinical translation and Precision Medicine – Shian-Ying Sung
14:00	Accelerating biomedical innovation with a strong clinical strategy – Jowy Tani
14:20	How VC and Accelerator Help Startups Hit New Heights – Arthur Chen
14:40	Open Discussion and closing remarks

CURRICURUM VITAE



Full Name: David Lee

Present Position : Chief Scientific Officer at Novartis (Taiwan) Co., Ltd.

Working Experience :

2020/7-Present: Chief Scientific Officer

2020/3– 2020/7: Clinical Development Unit Head, Opthamology a.i , Global Drug Development : Shanghai City, China

2019/6-2020/7: Clinical Development Unit Head, Cardio Renal Metabolism, Global Drug Development : Shanghai City, China

2017/10-2019/6: Worldwide Medical Affairs Director, Worldwide Medical Affairs : Basel Area, Switzerland

2015/11-2017/10: Worldwide Medical Affairs Associate Director, Worldwide Medical Affairs : Basel Area, Switzerland

2014/1-2015/10: Asia Cluster Medical Lead : Taiwan

Topic: The road to developing innovative and life-changing Medicine.

Speaker: Lee, David JS

CURRICURUM VITAE



Full Name: Hideki Hanaoka

Dr. Hideki HANAOKA is a Director of Clinical Research Center (CCRC), Professor, Chiba University Hospital, Japan, (July, 2010 - present), and a Vice Director of Future Medicine Research Center, Chiba University (January 2012 - present). CCRC is an ARO that has 80 staffs and he is a leader of CCRC. He has been working at CCRC, Chiba University Hospital, since 2003 after his career at Reviewer of New Drug Evaluation Team, Evaluation Division 2, Pharmaceuticals and Medical Devices Evaluating, National Institute of Health, MHLW, Japan, (2000 - 2003).

Education:

Ph.D. in Medicine; Chiba University Graduate School of Medicine, Japan, March 2001

Doctor of Medicine; Chiba University, Medical School, Japan, March 1993

Licensure and Certification:

Japanese Medical License Registration, 1993

Board Certified Allergy Specialists of Japanese Society of Allergy 2004

Board Certified Member of the Japanese Society of Internal Medicine, 2004

Board Certified Clinical Pharmacology Specialists of Japanese Society of Clinical Pharmacology and Therapeutics, 2009

Topic: What is necessary for ARO in Japan to overcome the COVID-19 crisis?

Speaker: Hideki Hanaoka

Curriculum Vitae

Name Oh, Sung Yong
Date of Birth Jan 13th, 1972
Address Dong-A University Medical Center, Oncology Department,
26 Daesingongwon-ro, Seo-gu, Busan, 49201, South Korea
Telephone +82-51-10-8624-9818, + 82-51-240-2808
FAX +82-51-246-5044 e-MAIL drosey@dau.ac.kr

Working Experiences

Professor

Dong-A University Medical center, Busan 2019.03~present

Associate Professor

Dong-A University Medical center, Busan 2014.03~2019.2

Assistant Professor

Dong-A University Medical center, Busan 2008.3~2014.02

Clinical Trial Instructor, Clinical fellowship

Dong-A University Medical center, Busan 2006.3~2008.2

Fellowship,

Samsung Medical Center, Seoul 2005.3~2006.2

Fellowship,

Dong-A University Medical center, Busan 2004.5~2005.2

Naval Medical Officer,

Military Service 2001.3~2004.4

Resident,

Samsung Medical Center, Seoul 1997.3~2001.2

Internship,

Samsung Medical Center, Seoul 1996.3~1997.2

◆ Educational Background

Dong-A University Graduate School, 2006.3~2008.2
PhD degree

Dong-A University Graduate School,
Master's degree

2004.3~2006.2

Dong-A University, Medical School
Bachelor's degree

1990.3~1996.2

Board Certifications

Diplomate, National Board of Medical Practitioner (No. 58345)

1996.2.

Certified in Internal Medicine,
Korea Board of Internal Medicine (No. 7339)

2001.2.

Certified in Hematology/Medical Oncology,
Korea Board of Internal Medicine (No. 6-06-278)

2006.9.

Topic: Clinical trial operation in Dong-A University Medical Center, South Korea

Speaker: Sung-Yong Oh

Audrey Ooi Joo Ann

Contact : +6012-6096583

E-mail : audrey.ooi@clinicalresearch.my

Summary

An experienced business development professional and a keen advocate of clinical research with experience in business development, project management, stakeholder management, medical writing and marketing.

Experience

Clinical Research Malaysia, Kuala Lumpur, Malaysia

Feb 2020 – Current	Head of Business Development
Feb 2019 – Feb 2020	Manager, Business Development
May 2018 – Jan 2019	Associate Manager, Business Development
March 2015 – May 2018	Senior Executive, Business Development
March 2014 – March 2015	Senior Executive, Communications and Relations

University Malaya, Kuala Lumpur, Malaysia

April 2012 – March 2014	Medical Writer
-------------------------	----------------

MediTech Media, Selangor, Malaysia

April 2011 – April 2012	Medical Writer
-------------------------	----------------

University of Malaya, Kuala Lumpur, Malaysia

July 2007 – July 2009	Research Assistant
-----------------------	--------------------

Education

2012	University of Malay (UM) Master's Degree in Medical Science Malaysia
2007	Monash University Bachelor's Degree in Medical Science Malaysia

Publication and Certification

Publications:

Tan BY, Ooi AJA, Mat Radi N (2020) To Participate or Not Participate: Why do Investigators Reject a Clinical Research *Journal for Clinical Studies*, Vol 12, Issue 4, 8 Sept 2020 <https://www.iforcs.com/to-participate-or-not-participate-why-do-investigators-reject-a-clinical-research/>

Mat Radi N, Tan BY, Ooi AJA (2020) Attracting Clinical Research to Malaysia with a Centralized Feasibility Platform. *Journal for Clinical Studies*. Vol 11 Issue 6 <https://www.iforcs.com/attracting-clinical-research-to-malaysia-with-a-centralised-feasibility-platform/>

Ooi AJA, Mat Radi N (2020) Establishing Clear Procedures and Improving Start-up Timeline in Malaysia's Clinical Research Ecosystem. Vol 12 Issue 3. <https://www.iforcs.com/establishing-clear-procedures-and-improving-start-up-timeline-in-malaysias-clinical-research-ecosystem/>

Ooi AJA, Khalid KF (2019) Initiatives to Establish Capabilities in Early Phase Clinical Research in Malaysia. *Applied Clinical Trials* Sep 26. <http://www.appliedclinicaltrialsonline.com/initiatives-establish-capabilities-early-phase-clinical-research-malaysia>

Ooi AJA, Khalid KF (2019) A unique model to accelerate industry-sponsored research in Malaysia. *Journal for Clinical Studies*. Vol 11 Issue 1. <https://www.iforcs.com/a-unique-model-to-accelerate-industrysponsored-research-in-malaysia/>

Ooi AJA, Khalid KF (2017) Malaysia's clinical research ecosystem. *Applied Clinical Trials*. Jan 26. <http://www.appliedclinicaltrialsonline.com/malaysia-s-clinical-research-ecosystem>

Chan, K.Y.; Mohamad, K.; Ooi, A.J.A.; Imiyabir, Z.; Chung, L.Y. (2012) Bioactivity-guided fractionation of the lipoxygenase and cyclooxygenase inhibiting constituents from *Chisocheton polyandrus* Merr. *Fitoterapia*, 83 (5). pp. 961-967. ISSN 0367-326X

Certification:

Good Clinical Practice (GCP), 2014

Achievement /Other Assignments

- Recipient of the 2017 CRM CEO Award
- Programme Committee and Session Chair for DIA Singapore Annual Meeting (2019 – current)
- Technical Committee Member for Bioequivalence Centre, Hospital UiTM (2020 – 2021)
- National Vaccine Development Roadmap Technical Working Group 2020/21
- Technical Working Group for Cell and Gene Therapy Products (2020-current)

Speaker: Audrey Ooi

This image shows a single sheet of white paper with horizontal blue or grey ruling lines, typical of notebook paper. The lines are evenly spaced and run across the width of the page. There is no handwriting or other markings on the paper.

CURRICURUM VITAE



Full Name : Bannakij Lojanapiwat

**Present Position: Special Expert Professor of Urology, Chiang Mai University, Thailand
:Dean of Faculty of Medicine, Chiang Mai University, Thailand**

**Academic or Medical Associations Position: President of
Thai Urologic Association**

Educational background & professional experience1988:

Medicine from Chiang Mai University

1992: Fellowship in Organ transplantation , Albert Einstein Medical Center, Philadelphia , USA2001:

Fellowship in Endourology, University of Miami, USA

Research Interests

Prostate Cancer, stone disease

Publications

-Lim J, Amantakul A, Shariff N, Lojanapiwat B, et al. Clinical outcomes of abiraterone acetate and predictors of its treatment duration in metastatic castration-resistant prostate cancer: Real- world experience in the Southeast Asian Cohort Cancer Med. 2020;9:4613-21.

-Uemura H, Ye D, Kanesvaran R, Chiong E, Lojanapiwat B, et al. United in Fight against prostate cancer (UFO) registry: first results from a large, multi- centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia. BJU Int. 2020;125:541-5.

-Chiong E, Murphy DG, Lojanapiwat B, et al ; ANZUP Cancer Trials Group, Management of patients with advanced prostate cancer in the Asia Pacific region: 'real- world' consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017..BJU Int. 2019;123:22-34.

Topic: Clinical trial operation in Chiang Mai University, Thailand

Speaker: Bannakij Lojanapiwat

Name: Shian-Ying Sung

Current Position:

2013 – present Associate Professor, Taipei Medical University

2018 – present Director, JCRC, Taipei Medical University

Educations:

2000 Ph.D. in Microbiol. & Immunol., Virginia Commonwealth Univ., Richmond, Virginia

Professional Experiences:

- 2019- Current Vice Dean, Office of Human Research, Taipei Medical University, Taipei Taiwan
- 2015 – 2019 Deputy Director, Join Clinical Research Center, Office of Human Research, Taipei Medical University, Taipei Taiwan
- 2012-2013 Associate Professor, Grad. Inst. Of Cancer Biol. China Medical Univ. School of Medicine, Taichung, Taiwan
- 2007 – 2013 Assistant Professor, Grad. Inst. of Cancer Biol., China Medical Univ. School of Medicine, Taichung, Taiwan
- 2006 – 2007 Instructor, Depts. of Urology & Radiation Oncology, Emory University School of Medicine, Atlanta, GA, USA

Selected Publications: (most recent 10 publications)

1. Do AD, Kurniawati I, HsiehCL, Wong TT, Lin YL, Sung SY. Application of Mesenchymal Stem Cells in Targeted Delivery to the Brain: Potential and Challenges of the Extracellular Vesicle-Based Approach for Brain Tumor Treatment. **Int. J. Mol. Sci.** **2021 Oct. 17**; 22(20): 11187
2. Huang SS, Liao WY, Hsu CC, Chan TS, Liao TY, Yang PM, Chen LT, Sung SY, Tsai KK. A novel invadopodia-specific marker for invasive and pro-metastatic cancer stem cells. **Frontier in Oncology**, **2021 May 31**; 11: 718849.
3. Su CM, Hsu TW, Sung SY, Huang MT, Chen KC, Huang CY, Chiang CY, Su YH, Chen HA, Liao PH. AXL is crucial for E1A-enhanced therapeutic efficiency of EGFR tyrosine kinase inhibitors through NFI in breast cancer. **Environ. Toxicol.** **2021 Mar 18**; 36(7): 1278-1287
4. Chen BW, Chiu GW, He YC, Huang CY, Huang HT, Sung SY, Hsieh CL, Chang WC, Hsu MS, Wei ZH, Yao DJ. Extracellular and intracellular intermittent magnetic-fluid hyperthermia treatment of SK-Hep1 hepatocellular carcinoma cells based on magnetic nanoparticles coated with polystyrene sulfonic acid. **PLoS One** **2021 Feb 5**; 16(2): e0245286.
5. Shigemura K, Sung SY, Fujisawa M. et al., Effect of Preoperative Dutasteride on Holmium Laser Enucleation of the Prostate. **Urol. Int.** **2020 Sep**; **104(5-6): 356-360.**
6. Chen BW, He YC, Sung SY, Yao DJ et al., Synthesis and characterization of magnetic nanoparticles coated with polystyrene sulfonic acid for biomedical applications. **Sci Technol Adv. Mater.** **2020 Jul 22**; **21(1): 471-481.**

7. Ishii A, Shigemura K, Sung SY, Fujisawa M et al., Anti-tumor Effect of Hedgehog Signaling Inhibitor, Vismodegib, on Castration-resistant Prostate Cancer. **Anticancer Res.**, 2020 Sep; 40(9): 5107-5114.
8. Yi-Te C., Sung SY, Fujisawa M et al., Urinary tract infection pathogens and antimicrobial susceptibilities in Kobe, Japan and Taipei, Taiwan: an international analysis. **J. Int. Med. Res.** 2020 Feb; 48(2): 300060519867826
9. Tran HM, Wu KS, Sung SY, Wong TT et al., Upregulation of Protein Synthesis and Proteasome Degradation Confers Sensitivity to Proteasome Inhibitor Bortezomib in Myc-Atypical Teratoid/Rhabdoid Tumors. **Cancers (Basel).** 2020 Mar 22; 12(3):752.
10. Wu KS, Sung SY, Wong TT et al., Molecular-Clinical Correlation in Pediatric Medulloblastoma: A Cohort Series Study of 52 Cases in Taiwan. **Cancers (Basel).** 2020 Mar 11; 12(3):653.

Topic: TMU as ARO to comprehensively enhance clinical trial services during the pandemic crisis

Speaker: Shian-Ying Sung

Katsumi Shigemura MD, PhD

Date of Birth 10/09/1972

Nationality: Japan

Address (work): 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Japan 650-0017

Tel: +81-78-382-6155

Fax: +81-78-382-6169

Work experience

1999May-1999Sep

Department of Neurosurgery, Kobe University Hospital

1999Oct-2000Mar

Department of Neurosurgery, Rokko-Island Hospital

2000Apr-2000Sep

Department of Urology, Kobe University Hospital

2000-2002

Department of Urology, Nishiwaki Municipal Hospital

2002-2004

Department of Urology, Kobe University Graduate School of Medicine (Graduate student)

2004 Apr-2004 Sep

Department of biochemistry and molecular biology, University of Arkansas for Medical Sciences (Research fellow)

2004 Oct-2007

Department of Urology, Emory University School of Medicine (USA) (Research fellow)

2007-2010

Department of Urology, Akashi Municipal Hospital (Department subhead)

2007 -2012

Department of Urology, Kobe University Graduate School of Medicine (Research Instructor)

2010-2012

Department of Urology, Shinko Hospital (Department head)

2012.4-2013.3

Department of Urology, Kobe University Graduate School of Medicine (Specially

appointed assistant professor (Part-time)

2013.4-2016.7

Department of Urology, Kobe University Graduate School of Medicine (Assistant Professor)

2016.8-

Department of Urology, Kobe University Hospital and Division of Infectious Diseases,
Department of International Health, Kobe University Graduate School of Health
Science (Associate Professor)

Education

1993-1999

Kochi Medical University

Degree

1999.3 MD (Kochi Medical University)

2006. 3 PhD (Department of Urology, Kobe University Graduate School of Medicine)

Professional qualification

1999. 4 MD certificate

2008 Urological specialist certificate

2013 Urological adviser certificate

Award

2007 Japanese Urological Association 65th Sakaguchi-award

2009 Young Research Contest award at West Japan Urological Association

2014 Reviewers of International Journal of Urology 2013

2014 Best Poster Award at 29th European Urological Association

Academic papers

1. Kitagawa K, **Shigemura K**, Ishii A, Nakashima T, Matsuo H, Takahashi Y, Omura

- S, Nakanishi J, Fujisawa M. Nanaomycin K inhibited epithelial mesenchymal transition and tumor growth in bladder cancer cells in vitro and in vivo. *Sci Rep*. 2021 Apr 28;11(1):9217.
2. **Shigemura K**, Fujisawa M. Editorial Comment. *J Urol*. 2021 Apr;205(4):997-998.
 3. Iqbal U, Durrani MM, Elsayed AS, Hussein AA, Shigemura K, Fujisawa M, Guru KA. Functional outcomes after robot-assisted radical cystectomy: A review of literature. *Int J Urol*. 2021 May;28(5):493-501.
 4. **Shigemura K**, Fujisawa M. Prevention and management of infectious complications in prostate biopsy: A review. *Int J Urol*. 2021 May 8.
 5. Takase Y, Yang YM, Kitagawa K, Nakano Y, Miura S, Oshikiri T, Kakeji Y, **Shigemura K**, Fujisawa M. Polymicrobial Solitary Retroperitoneal Abscess Due to Sigmoid Colon Perforation. *Kobe J Med Sci*. 2021 Jan 4;66(4):E149-E152.
 6. Ishii A, **Shigemura K**, Kitagawa K, Harada M, Kan Y, Hayashi F, Osawa K, Kuntaman K, Shirakawa T, Fujisawa M. Cross-Resistance and the Mechanisms of Cephalosporin-Resistant Bacteria in Urinary Tract Infections Isolated in Indonesia. *Curr Microbiol*. 2021 May;78(5):1771-1777.
 7. Wada K, Yokoyama T, Uno S, Araki M, Sadahira T, Maruyama Y, Acosta H, Nakajima H, Hiyama Y, Kunishima Y, Togo Y, Nukaya T, Yamada H, **Shigemura K**, Ito S, Tanimura M, Kobayashi K, Kitano H, Teishima J, Yasuda M, Uehara S, Hamasuna R, Watanabe T, Nakagawa T, Hayami H, Miyazaki J, Takahashi S, Masumori N, Ishikawa K, Kiyota H, Fujisawa M, Arakawa S, Nasu Y, Yamamoto S. Nationwide surveillance of bacterial pathogens isolated from patients with acute uncomplicated cystitis in 2018: Conducted by the Japanese Research Group for Urinary Tract Infections (JRGU). *J Infect Chemother*. 2021 Apr 13:S1341-321X(21)00086-6.
 8. Yang YM, Osawa K, Kitagawa K, Hosoya S, Onishi R, Ishii A, Shirakawa T, Hirai I, Kuntaman K, Tanimoto H, Shigemura K, Fujisawa M. Differential effects of chromosome and plasmid blaCTX-M-15 genes on antibiotic susceptibilities in extended-spectrum beta-lactamase-producing *Escherichia coli* isolates from patients

with urinary tract infection. *Int J Urol*. 2021 Apr 2.

9. Elsayed AS, Aldhaam NA, Nitsche L, Siam A, Jing Z, Hussein AA, **Shigemura K**, Fujisawa M, Guru KA. Robot-assisted radical cystectomy: Review of surgical technique, and perioperative, oncological and functional outcomes. *Int J Urol*. 2020 Mar;27(3):194-205.
10. Uda A, **Shigemura K**, Kitagawa K, Osawa K, Onuma K, Yan Y, Nishioka T, Fujisawa M, Yano I, Miyara T. Risk Factors for the Acquisition of Enterococcus faecium Infection and Mortality in Patients with Enterococcal Bacteremia: A 5-Year Retrospective Analysis in a Tertiary Care University Hospital. *Antibiotics (Basel)*. 2021 Jan 11;10(1):E64.
11. Matsuo H, Nakanishi J, Noguchi Y, Kitagawa K, **Shigemura K**, Sunazuka T, Takahashi Y, Ōmura S, Nakashima T. Nanaomycin K, a new epithelial-mesenchymal transition inhibitor produced by the actinomycete "Streptomyces rosa subsp. notoensis" OS-3966. *J Biosci Bioeng*. 2020 Mar;129(3):291-295.
12. Kanzawa M, Fukuoka H, Yamamoto A, Suda K, **Shigemura K**, Hara S, Imagawa N, Tsukamoto R, Aoyama Y, Nakamura Y, Fujisawa M, Ogawa W, Takahashi Y, Itoh T. Adrenal Corticomedullary Mixed Tumor Associated With the FGFR4-G388R Variant. *J Endocr Soc*. 2020 Jul 21;4(9):bvaa101.
13. Ishii A, **Shigemura K**, Kitagawa K, Sung SY, Chen KC, Yi-Te C, Liu MC, Fujisawa M. Anti-tumor Effect of Hedgehog Signaling Inhibitor, Vismodegib, on Castration-resistant Prostate Cancer. *Anticancer Res*. 2020 Sep;40(9):5107-5114.
14. Fukuoka H, **Shigemura K**, Kanzawa M, Kanda T, Yamamoto M, Kitagawa K, Sakamoto M, Iguchi G, Ogawa W, Fujisawa M, Takahashi Y. The impact of adrenal tumor multidisciplinary team meetings on clinical outcomes. *Endocrine*. 2020 Sep;69(3):519-525.
15. Yamasaki S, **Shigemura K**, Osawa K, Kitagawa K, Ishii A, Kuntaman K, Shirakawa T, Miyara T, Fujisawa M. Genetic analysis of ESBL-producing Klebsiella pneumoniae isolated from UTI patients in Indonesia. *J Infect Chemother*. 2021 Jan;27(1):55-61.

16. Osawa K, **Shigemura K**, Kitagawa K, Kuntaman K, Mertaniasih NM, Setyarini W, Arizandy D, Rahadjo D, Osawa R, Shirakawa T, Fujisawa M. Difference of Phenotype and Genotype Between Human and Environmental: Isolated *Vibrio cholerae* in Surabaya, Indonesia. *Indian J Microbiol*. 2020 Jun;60(2):230-238.
17. Yi-Te C, **Shigemura K**, Nishimoto K, Yamada N, Kitagawa K, Sung SY, Chen KC, Fujisawa M. Urinary tract infection pathogens and antimicrobial susceptibilities in Kobe, Japan and Taipei, Taiwan: an international analysis. *J Int Med Res*. 2020 Feb;48(2):300060519867826.
18. **Shigemura K**, Kitagawa K, Nomi M, Yanagiuchi A, Sengoku A, Fujisawa M. Risk factors for febrile genito-urinary infection in the catheterized patients by with spinal cord injury-associated chronic neurogenic lower urinary tract dysfunction evaluated by urodynamic study and cystography: a retrospective study. *World J Urol*. 2020 Mar;38(3):733-740.
19. Yuri P, **Shigemura K**, Kitagawa K, Hadibrata E, Risan M, Zulfiqqar A, Soeroharjo I, Hendri AZ, Danarto R, Ishii A, Yamasaki S, Yan Y, Heriyanto DS, Fujisawa M. Increased tumor-associated macrophages in the prostate cancer microenvironment predicted patients' survival and responses to androgen deprivation therapies in Indonesian patients cohort. *Prostate Int*. 2020 Jun;8(2):62-69.
20. Maeshige N, Kitagawa K, Yamasaki S, Ishii A, Shirakawa T, Yang YM, Sung SY, Chen KC, Yuan ZM, **Shigemura K**, Fujisawa M. Can ultrasound irradiation be a therapeutic option for prostate cancer? *Prostate*. 2020 Jun 18.
21. Kitano H, Shigemoto N, Koba Y, Hara T, Seiya K, Omori K, **Shigemura K**, Teishima J, Fujisawa M, Matsubara A, Ohge H. Indwelling catheterization, renal stones, and hydronephrosis are risk factors for symptomatic *Staphylococcus aureus*-related urinary tract infection. *World J Urol*. 2020 May 3.
22. Fardah Athiyyah A, **Shigemura K**, Kitagawa K, Agustina N, Darma A, Ranuh R, Raharjo D, Shirakawa T, Fujisawa M, Marto Sudarmo S. Clinical manifestation of norovirus infection in children aged less than five years old admitted with acute diarrhea in Surabaya, Indonesia: a cross-sectional study. *Version 3. F1000Res*. 2019 Dec 20;8:2130.

23. Osawa K, **Shigemura K**, Kitagawa K, Kuntaman K, Mertaniasih NM, Setyarini W, Arizandy D, Rahadjo D, Osawa R, Shirakawa T, Fujisawa M. Difference of Phenotype and Genotype Between Human and Environmental: Isolated *Vibrio cholerae* in Surabaya, Indonesia. *Indian J Microbiol*. 2020 Jun;60(2):230-238.
24. Suda K, Fukuoka H, Yamazaki Y, **Shigemura K**, Mukai M, Odake Y, Matsumoto R, Bando H, Takahashi M, Iguchi G, Fujisawa M, Oka M, Ono K, Chihara K, Sasano H, Ogawa W, Takahashi Y. Cardiac Myxoma Caused by Fumarate Hydratase Gene Deletion in Patient With Cortisol-Secreting Adrenocortical Adenoma. *J Clin Endocrinol Metab*. 2020 Jun 1;105(6):dgaa163.
25. Uda A, **Shigemura K**, Kitagawa K, Osawa K, Onuma K, Inoue S, Kotani J, Yan Y, Nakano Y, Nishioka T, Yano I, Miyara T, Fujisawa M. How Does Antimicrobial Stewardship Affect Inappropriate Antibiotic Therapy in Urological Patients? *Antibiotics (Basel)*. 2020 Feb 6;9(2):63.
26. Elsayed AS, Aldhaam NA, Nitsche L, Siam A, Jing Z, Hussein AA, **Shigemura K**, Fujisawa M, Guru KA. Robot-assisted radical cystectomy: Review of surgical technique, and perioperative, oncological and functional outcomes. *Int J Urol*. 2020 Mar;27(3):194-205.
27. Kitagawa K, **Shigemura K**, Nomi M, Takami N, Yamada N, Fujisawa M. Use of oral third generation cephalosporins and quinolones and occurrence of antibiotic-resistant strains in the neurogenic bladder (NB) outpatient setting: a retrospective chart audit. *Spinal Cord*. 2020 Jun;58(6):705-710.
28. **Shigemura K**, Kitagawa K, Chen KC, Sung SY, Fujisawa M. Effect of Preoperative Dutasteride on Holmium Laser Enucleation of the Prostate. *Urol Int*. 2019 Dec 4;1-5.
29. Uda A, Tokimatsu I, Koike C, Osawa K, **Shigemura K**, Kimura T, Miyara T, Yano I. Antibiotic de-escalation therapy in patients with community-acquired nonbacteremic pneumococcal pneumonia. *Int J Clin Pharm*. 2019 Dec;41(6):1611-1617.

30. Teramae M, Osawa K, **Shigemura K**, Kitagawa K, Shirakawa T, Fujisawa M, Miyara T. Prevalence of Quinolone Resistance of Extended-Spectrum β -Lactamase-Producing *Escherichia coli* with ST131-*fimH30* in a City Hospital in Hyogo, Japan. *Int J Mol Sci*. 2019 Oct 18;20(20).
31. Suzuki K, Terakawa T, **Shigemura K**, Furukawa J, Harada K, Hinata N, Nakano Y, Fujisawa M. Identification of favorable subgroups for alternative anti-androgen therapy in castration-resistant prostate cancer. *Mol Clin Oncol*. 2019 Nov;11(5):523-530.
32. Matsuo H, Nakanishi J, Noguchi Y, Kitagawa K, **Shigemura K**, Sunazuka T, Takahashi Y, Ōmura S, Nakashima T. Nanaomycin K, a new epithelial-mesenchymal transition inhibitor produced by the actinomycete "Streptomyces rosa subsp. notoensis" OS-3966. *J Biosci Bioeng*. 2019 Sep 30.
33. **Shigemura K**, Sung SY, Chen KC, Fujisawa M. Comment for "nomogram establishment for surgery-related complications in partial nephrectomy". *Ann Transl Med*. 2019 Jul;7(Suppl 3):S120.
34. Kitano H, Teishima J, **Shigemura K**, Ohge H, Fujisawa M, Matsubara A. Current status of countermeasures for infectious diseases and resistant microbes in the field of urology. *Int J Urol*. 2019 Dec;26(12):1090-1098.
35. Kitagawa K, **Shigemura K**, Sung SY, Chen KC, Huang CC, Chiang YT, Liu MC, Huang TW, Yamamichi F, Shirakawa T, Fujisawa M. Possible correlation of sonic hedgehog signaling with epithelial-mesenchymal transition in muscle-invasive bladder cancer progression. *J Cancer Res Clin Oncol*. 2019 Sep;145(9):2261-2271.
36. **Shigemura K**, Fujisawa M. Editorial Comment to Quality of life after external beam radiotherapy for localized prostate cancer: Comparison with other modalities. *Int J Urol*. 2019 Oct;26(10):954-955.
37. **Shigemura K**, Yamamichi F, Nishimoto K, Kitagawa K, Fujisawa M. Protocol for a comparison study of 1-day (single dose) versus 2-day prophylactic antibiotic administration in Holmium Laser enucleation of the prostate (HoLEP): a

randomized controlled trial. Version 2. F1000Res. 2019 Feb 6 [revised 2019 Jan 1];8:161.

38. **Shigemura K**, Fujisawa M. Editorial Comment to Potential of hyperbaric oxygen in urological diseases. *Int J Urol*. 2019 Sep;26(9):867.
39. **Shigemura K**, Kitagawa K, Nomi M, Yanagiuchi A, Sengoku A, Fujisawa M. Risk factors for febrile genito-urinary infection in the catheterized patients by with spinal cord injury-associated chronic neurogenic lower urinary tract dysfunction evaluated by urodynamic study and cystography: a retrospective study. *World J Urol*. 2019 Apr 4.
40. **Shigemura K**, Tanaka K, Hamasuna R, Ishikawa K, Matsumoto T, Arakawa S, Kiyota H, Yamamoto S, Fujisawa M; Japanese Research Group for Urinary Tract Infection (JRGU). Efficacy of Prophylactic Antimicrobial Administration of Tazobactam/Piperacillin for Radical Cystectomy with Urinary Diversion: A Multicenter Study. *Urol Int*. 2019;102(3):293-298.
41. Hasso-Agopsowicz M, Ladva CN, Lopman B, Sanderson C, Cohen AL, Tate JE, Riveros X, Henao-Restrepo AM, Clark A; Global Rotavirus Surveillance Network and **Rotavirus Age Study Collaborators**. Global Review of the Age Distribution of Rotavirus Disease in Children Aged <5 Years Before the Introduction of Rotavirus Vaccination. *Clin Infect Dis*. 2019 Aug 30;69(6):1071-1078.
42. **Shigemura K**, Fujisawa M. Editorial Comment to Updates in endourological management of urolithiasis. *Int J Urol*. 2019 Feb;26(2):183-184.
43. Mita Y, **Shigemura K**, Osawa K, Kitagawa K, Kotaki T, Shirakawa T, Miyara T, Fujisawa M. Clinical Risk Factors for Death Caused by Extended-Spectrum Beta-Lactamase: Producing Bacteria. *Urol Int*. 2019 Jan 2:1-7.
44. Kitagawa K, **Shigemura K**, Yamamichi F, Osawa K, Uda A, Koike C, Tokimatsu I, Shirakawa T, Miyara T, Fujisawa M. Bacteremia complicating urinary tract infection by *Pseudomonas aeruginosa*: Mortality risk factors. *Int J Urol*. 2018 Dec 21.

45. Kimura T, Suga T, Kameoka M, Ueno M, Inahashi Y, Matsuo H, Iwatsuki M, **Shigemura K**, Shiomi K, Takahashi Y, Ōmura S, Nakashima T. New tetrahydroquinoline and indoline compounds containing a hydroxy cyclopentenone, virantmycin B and C, produced by *Streptomyces* sp. AM-2504. *J Antibiot (Tokyo)*. 2018 Dec 10.
46. Matsuo H, Noguchi Y, Také A, Nakanishi J, **Shigemura K**, Sunazuka T, Takahashi Y, Ōmura S, Nakashima T. Nanaomycin I and J: New nanaomycins generated by mycothiol-mediated compounds from "*Streptomyces rosa* subsp. *notoensis*" OS-3966. *J Biosci Bioeng*. 2018 Nov 29.
47. Shiraishi Y, Terakawa T, Jimbo N, **Shigemura K**, Hinata N, Fujisawa M. Total necrosis after sequential treatment with pazopanib followed by nivolumab in a patient with renal cell carcinoma involving the inferior vena cava. *Int J Urol*. 2018 Nov 14.
48. Osawa K, **Shigemura K**, Kitagawa K, Fukuda T, Takasaka A, Wakabayashi S, Sato K, Yamamichi F, Shirakawa T, Fujisawa M. Molecular characteristics of carbapenem-resistant *Pseudomonas aeruginosa* isolated from urine in Hyogo, Japan. *Int J Urol*. 2018 Oct 11.
49. Yamamichi F, **Shigemura K**, Kitagawa K, Fujisawa M. Predictive factors of improvement for voiding symptoms after holmium laser enucleation of the prostate. *Int J Urol*. 2018 Oct 11.
50. Kuntaman K, **Shigemura K**, Osawa K, Kitagawa K, Sato K, Yamada N, Nishimoto K, Yamamichi F, Rahardjo D, Hadi U, Mertaniasih NM, Kinoshita S, Fujisawa M, Shirakawa T. Occurrence and characterization of carbapenem-resistant Gram-negative bacilli: A collaborative study of antibiotic-resistant bacteria between Indonesia and Japan. *Int J Urol*. 2018 Nov;25(11):966-972.
51. Yamamichi F, Shigemura K, Kitagawa K, Fujisawa M. Comparison between non-septic and septic cases in stone-related obstructive acute pyelonephritis and risk factors for septic shock: A multi-center retrospective study. *J Infect Chemother*. 2018 Nov;24(11):902-906.

52. Nakanishi N, Nomoto R, Sato K, Koike C, Kusuki M, Nakamura T, **Shigemura K**, Shirakawa T, Fujisawa M, Tokimatsu I, Osawa K. Acquisition of antimicrobial-resistant variants in repeated infections caused by *Pseudomonas aeruginosa* revealed by whole genome sequencing. *J Infect Chemother*. 2018 Aug 17.
53. Tokimatsu I, **Shigemura K**, Osawa K, Kinugawa S, Kitagawa K, Nakanishi N, Yoshida H, Arakawa S, Fujisawa M; Research Group of Japan Infection Prevention and Control Conference for National and Public University Hospitals. Molecular epidemiologic study of *Clostridium difficile* infections in university hospitals: Results of a nationwide study in Japan. *J Infect Chemother*. 2018 Apr 20.
54. Osawa K, **Shigemura K**, Kitagawa K, Tokimatsu I, Fujisawa M. Risk factors for death from *Stenotrophomonas maltophilia* bacteremia. *J Infect Chemother*. 2018 Apr 16.
55. Terakawa T, Hussein AA, Bando Y, Guru KA, Furukawa J, **Shigemura K**, Harada K, Hinata N, Nakano Y, Fujisawa M. Presurgical pazopanib for renal cell carcinoma with inferior vena caval thrombus: a single-institution study. *Anticancer Drugs*. 2018 Apr 6.
56. Kusuki M, Osawa K, Arikawa K, Tamura M, **Shigemura K**, Shirakawa T, Nakamura T, Nakamachi Y, Fujisawa M, Saegusa J, Tokimatsu I. Determination of the antimicrobial susceptibility and molecular profile of clarithromycin resistance in the *Mycobacterium abscessus* complex in Japan by variable number tandem repeat analysis. *Diagn Microbiol Infect Dis*. 2018 Feb 18.
57. Ikeda Y, **Shigemura K**, Nomi M, Tabata C, Kitagawa K, Arakawa S, Fujisawa M. Infection Control Following an Outbreak of Extended-Spectrum Beta-Lactamase-Producing *Klebsiella pneumoniae* Isolated from Catheter-Associated Urinary Tract Infection. *Jpn J Infect Dis*. 2018 Mar 22;71(2):158-161.
58. **Shigemura K**, Yamamichi F, Fujisawa M. Editorial Comment to Summary of the UAA-AAUS guidelines for urinary tract infections. *Int J Urol*. 2018 Mar;25(3):185-186.
59. **Shigemura K**, Fujisawa M. Current status of holmium laser enucleation of the

prostate. *Int J Urol*. 2017 Dec 3.

60. Kitagawa K, **Shigemura K**, Yamamichi F, Alimsardjono L, Rahardjo D, Kuntaman K, Shirakawa T, Fujisawa M. International Comparison of Causative Bacteria and Antimicrobial Susceptibilities of Urinary Tract Infections between Kobe, Japan, and Surabaya, Indonesia. *Jpn J Infect Dis*. 2018 Jan 23;71(1):8-13.
61. **Shigemura K**, Fujisawa M. Editorial Comment to Diagnosis and treatment of patients with prostatic abscess in the post-antibiotic era. *Int J Urol*. 2018 Feb;25(2):110-111.
62. **Shigemura K**, Kitagawa K, Osawa K, Yamamichi F, Tokimatsu I, Nomi M, Takaba K, Fujisawa M. Comparison of antibiotics use, urinary tract infection (UTI)-causative bacteria and their antibiotic susceptibilities among 4 hospitals with different backgrounds and regions in Japan. *J Chemother*. 2018 Feb;30(1):31-36.
63. Hsieh CL, Liu CM, Chen HA, Yang ST, **Shigemura K**, Kitagawa K, Yamamichi F, Fujisawa M, Liu YR, Lee WH, Chen KC, Shen CN, Lin CC, Chung LWK, Sung SY. Reactive oxygen species-mediated switching expression of MMP-3 in stromal fibroblasts and cancer cells during prostate cancer progression. *Sci Rep*. 2017 Aug 22;7(1):9065.
64. Kitagawa K, **Shigemura K**, Onuma KI, Nishida M, Fujiwara M, Kobayashi S, Yamasaki M, Nakamura T, Yamamichi F, Shirakawa T, Tokimatsu I, Fujisawa M. Improved bacterial identification directly from urine samples with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. *J Clin Lab Anal*. 2017 Jul 24.
65. **Shigemura K**, Fujisawa M. Editorial Comment to Prevention of infectious complications after prostate biopsy procedure. *Int J Urol*. 2017 Jul;24(7):492.
66. **Shigemura K**, Fujisawa M. Editorial Comment to Substitution urethroplasty using oral mucosa graft for male anterior urethral stricture disease: Current topics and reviews. *Int J Urol*. 2017 Jul;24(7):503-504.
67. Osawa K, **Shigemura K**, Nukata Y, Kitagawa K, Yamamichi F, Yoshida H,

- Shirakawa T, Arakawa S, Fujisawa M. penA, ponA, porB1, and mtrR Mutations and Molecular Epidemiological Typing of *Neisseria gonorrhoeae* with Decreased Susceptibility to Cephalosporins. *Antimicrob Agents Chemother*. 2017 Jul 25;61(8). pii: e01174-17.
68. Tokimatsu I, **Shigemura K**, Kotaki T, Yoshikawa H, Yamamichi F, Tomo T, Arakawa S, Fujisawa M, Kadota JI. A Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia. *Intern Med*. 2017;56(11):1315-1319.
69. **Shigemura K**, Fujisawa M. Editorial Comment to Pelvic floor muscle therapy or alpha-blocking agents for treatment of men with lower urinary tract symptoms: An exploratory randomized controlled trial. *Int J Urol*. 2017 Jun;24(6):475.
70. Yamamichi F, **Shigemura K**, Arakawa S, Fujisawa M. What are the differences between older and younger patients with epididymitis? *Investig Clin Urol*. 2017 May;58(3):205-209.
71. **Shigemura K**, Yamamichi F, Kitagawa K, Yamashita M, Oka Y, Tanaka H, Fujisawa M. Does Surgeon Experience Affect Operative Time, Adverse Events and Continence Outcomes in Holmium Laser Enucleation of the Prostate? A Review of More Than 1,000 Cases. *J Urol*. 2017 Sep;198(3):663-670.
72. Yamamichi F, **Shigemura K**, Kitagawa K, Takaba K, Tokimatsu I, Arakawa S, Fujisawa M. Shock due to urosepsis: A multicentre study. *Can Urol Assoc J*. 2017 Mar-Apr;11(3-4):E105-E109.
73. Mukai S, **Shigemura K**, Yamamichi F, Kitagawa K, Takami N, Nomi M, Arakawa S, Fujisawa M. Comparison of cost-effectiveness between the quantiFERON-TB Gold-In-Tube and T-Spot tests for screening health-care workers for latent tuberculosis infection. *Int J Mycobacteriol*. 2017 Jan-Mar;6(1):83-86.
74. Kitagawa K, Oda T, Saito H, Araki A, Gonoi R, **Shigemura K**, Hashii Y, Katayama T, Fujisawa M, Shirakawa T. Development of oral cancer vaccine using recombinant *Bifidobacterium* displaying Wilms' tumor 1 protein. *Cancer Immunol Immunother*. 2017 Jun;66(6):787-798.

75. **Shigemura K**, Fujisawa M. Editorial Comment to From evidence-based medicine to evidence-balanced medicine for individualized and personalized care: As applied to benign prostatic hyperplasia/male lower urinary tract symptoms. *Int J Urol*. 2017 Feb;24(2):95-96.
76. Yamamichi F, **Shigemura K**, Kitagawa K, Arakawa S, Tokimatsu I, Fujisawa M. Should We Change the Initial Treatment of Renal or Retroperitoneal Abscess in High Risk Patients? *Urol Int*. 2017;98(2):222-227.
77. Kitagawa K, Omoto C, Oda T, Araki A, Saito H, **Shigemura K**, Katayama T, Hotta H, Shirakawa T. Oral Combination Vaccine, Comprising Bifidobacterium Displaying Hepatitis C Virus Nonstructural Protein 3 and Interferon- α , Induces Strong Cellular Immunity Specific to Nonstructural Protein 3 in Mice. *Viral Immunol*. 2017 Apr;30(3):196-203.
78. Bagus Wasito E, **Shigemura K**, Osawa K, Fardah A, Kanaida A, Raharjo D, Kuntaman K, Hadi U, Harijono S, Marto Sudarmo S, Nakamura T, Shibayama K, Fujisawa M, Shirakawa T. Antibiotic Susceptibilities and Genetic Characteristics of Extended-Spectrum Beta-Lactamase-Producing *Escherichia coli* Isolates from Stools of Pediatric Diarrhea Patients in Surabaya, Indonesia. *Jpn J Infect Dis*. 2017 Jul 24;70(4):378-382.
79. Yasuda M, Muratani T, Ishikawa K, Kiyota H, Sakata H, **Shigemura K**, Takahashi S, Hamasuna R, Hayami H, Mikamo H, Yamamoto S, Watanabe T, Arakawa S. Japanese guideline for clinical research of antimicrobial agents on urogenital infections: Second edition. *J Infect Chemother*. 2016 Oct;22(10):651-61.
80. **Shigemura K**, Fujisawa M. Editorial Comment to Postoperative infectious complications in patients undergoing holmium laser enucleation of the prostate: Risk factors and microbiological analysis. *Int J Urol*. 2016 Sep;23(9):796.
81. Yamamoto S, **Shigemura K**, Kiyota H, Wada K, Hayami H, Yasuda M, Takahashi S, Ishikawa K, Hamasuna R, Arakawa S, Matsumoto T; Japanese Research Group for UTI. Essential Japanese guidelines for the prevention of perioperative infections in the urological field: 2015 edition. *Int J Urol*. 2016 Oct;23(10):814-824.

82. Liu CM, Hsieh CL, Shen CN, Lin CC, **Shigemura K**, Sung SY. Exosomes from the tumor microenvironment as reciprocal regulators that enhance prostate cancer progression. *Int J Urol*. 2016 Sep;23(9):734-44.
83. **Shigemura K**, Fujisawa M. Editorial Comment to Testicular torsion-detorsion and potential therapeutic treatments: A possible role for ischemic postconditioning. *Int J Urol*. 2016 May 15.
84. **Shigemura K**, Tanaka K, Yamamichi F, Chiba K, Fujisawa M. Comparison of Predictive Factors for Postoperative Incontinence of Holmium Laser Enucleation of the Prostate by the Surgeons' Experience During Learning Curve. *Int Neurourol J*. 2016 Mar;20(1):59-68.
85. Li X, Wu JB, Li Q, **Shigemura K**, Chung LW, Huang WC. SREBP-2 promotes stem cell-like properties and metastasis by transcriptional activation of c-Myc in prostate cancer. *Oncotarget*. 2016 Mar 15;7(11):12869-84.
86. Osawa K, **Shigemura K**, Shirai H, Kato A, Okuya Y, Jikimoto T, Arakawa S, Fujisawa M, Shirakawa T. BACTERIAL IDENTIFICATION USING SSRA ENCODING TRANSFER-MESSENGER RNA. *Southeast Asian J Trop Med Public Health*. 2015 Jul;46(4):720-7.
87. Yamamichi F, **Shigemura K**, Behnsawy HM, Yamashita M, Shirakawa T, Fujisawa M. Beta-3 adrenergic receptors could be significant factors for overactive bladder-related symptoms. *Int J Clin Exp Pathol*. 2015 Sep 1;8(9):11863-70. eCollection 2015.
88. **Shigemura K**, Fujisawa M. Editorial Comment from Dr Shigemura and Dr Fujisawa to Predictive value of urinary interleukin-6 for symptomatic urinary tract infections in a nursing home population. *Int J Urol*. 2015 Nov 19.
89. Mukai S, **Shigemura K**, Nomi M, Sengoku A, Yamamichi F, Fujisawa M, Arakawa S. Retrospective study for risk factors for febrile UTI in spinal cord injury patients with routine concomitant intermittent catheterization in outpatient settings. *Spinal Cord*. 2016 Jan;54(1):69-72.

90. **Shigemura K**, Tanaka K, Yamamichi F, Arakawa S, Fujisawa M. Prophylactic efficacy of cephamycin plus fluoroquinolones in high risk patients on inhibiting infectious complications after transrectal prostate biopsy. *J Chemother*. 2016 May 24;1-4.
91. Yamamichi F, **Shigemura K**, Arakawa S, Tanaka K, Fujisawa M. CD-163 correlated with symptoms (pain or discomfort) of prostatic inflammation. *Int J Clin Exp Pathol*. 2015 Mar 1;8(3):2408-14. eCollection 2015.
92. **Shigemura K**, Osawa K, Yamamichi F, Tanaka K, Tokimatsu I, Arakawa S, Fujisawa M. Optimal vancomycin doses for methicillin-resistant *Staphylococcus aureus* infection in urological renal dysfunction patients. *Int Urol Nephrol*. 2015 Jun;47(6):887-91.
93. **Shigemura K**, Osawa K, Kato A, Tokimatsu I, Arakawa S, Shirakawa T, Fujisawa M. Association of overexpression of efflux pump genes with antibiotic resistance in *Pseudomonas aeruginosa* strains clinically isolated from urinary tract infection patients. *J Antibiot (Tokyo)*. 2015 Sep;68(9):568-72.
94. Sudarmo SM, **Shigemura K**, Athiyyah AF, Osawa K, Wardana OP, Darma A, Ranuh R, Raharjo D, Arakawa S, Fujisawa M, Shirakawa T. Genotyping and clinical factors in pediatric diarrhea caused by rotaviruses: one-year surveillance in Surabaya, Indonesia. *Gut Pathog*. 2015 Feb 8;7:3.
95. **Shigemura K**, Osawa K, Miura M, Tanaka K, Arakawa S, Shirakawa T, Fujisawa M. Azithromycin resistance and its mechanism in *Neisseria gonorrhoeae* strains in Hyogo, Japan. *Antimicrob Agents Chemother*. 2015 May;59(5):2695-9.
96. **Shigemura K**, Fujisawa M. Hedgehog signaling and urological cancers. *Curr Drug Targets*. 2015;16(3):258-71.
97. **Shigemura K**, Fujisawa M. History and epidemiology of antibiotic susceptibilities of *Neisseria gonorrhoeae*. *Curr Drug Targets*. 2015;16(3):272-80.

98. Osawa K, **Shigemura K**, Shimizu R, Kato A, Kusuki M, Jikimoto T, Nakamura T, Yoshida H, Arakawa S, Fujisawa M, Shirakawa T. Molecular characteristics of extended-spectrum β -lactamase-producing *Escherichia coli* in a university teaching hospital. *Microb Drug Resist*. 2015 Apr;21(2):130-9.
90. Yamamichi F, **Shigemura K**, Behnsawy HM, Meligy FY, Huang WC, Li X, Yamanaka K, Hanioka K, Miyake H, Tanaka K, Kawabata M, Shirakawa T, Fujisawa M. Sonic hedgehog and androgen signaling in tumor and stromal compartments drives epithelial-mesenchymal transition in prostate cancer. *Scand J Urol*. 2014 Dec;48(6):523-32.
100. Yamamichi F, **Shigemura K**, Yamashita M, Tanaka K, Arakawa S, Fujisawa M. Postoperative wound dealing and superficial surgical site infection in open radical prostatectomy. *Int Wound J*. 2014 Sep 4.
101. **Shigemura K**, Takase R, Osawa K, Takaba K, Nomi M, Fujisawa M, Arakawa S. Emergence and prevention measures for multidrug resistant *Pseudomonas aeruginosa* in catheter-associated urinary tract infection in spinal cord injury patients. *Spinal Cord*. 2015 Jan;53(1):70-4.
102. Tanaka K, **Shigemura K**, Hinata N, Muramaki M, Miyake H, Fujisawa M. Histological evaluation of nerve sparing technique in robotic assisted radical prostatectomy. *Indian J Urol*. 2014 Jul;30(3):268-72.
103. Tanaka K, Furukawa J, **Shigemura K**, Hinata N, Ishimura T, Muramaki M, Miyake H, Fujisawa M. Surgery-related outcomes and postoperative split renal function by scintigraphy evaluation in robot-assisted partial nephrectomy in complex renal tumors: an initial case series. *J Endourol*. 2015 Jan;29(1):29-34.
104. Yasuda M, Nakane K, Yamada Y, Matsumoto M, Sho T, Matsumoto M, Kobayashi K, **Shigemura K**, Nakano Y, Tanaka K, Hamasuna R, Ishihara S, Arakawa S, Yamamoto S, Matsubara A, Fujisawa M, Deguchi T, Matsumoto T. Clinical effectiveness and safety of tazobactam/piperacillin 4.5 g for the prevention of febrile infectious complication after prostate biopsy. *J Infect Chemother*. 2014 Oct;20(10):631-4.

105. Saito H, Ando S, Morishita N, Lee KM, Dator D, Dy D, **Shigemura K**, Adhim Z, Nibu K, Fujisawa M, Shirakawa T. A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma. *Anticancer Res.* 2014 Jul;34(7):3365-70.
106. Shimizu R, Osawa K, **Shigemura K**, Yoshida H, Fujiwara M, Iijima Y, Fujisawa M, Shirakawa T. Development of multiplex PCR for rapid identification of four *Salmonella* serovars most commonly isolated in Japan. *Southeast Asian J Trop Med Public Health.* 2014 May;45(3):654-61.
107. Osawa K, **Shigemura K**, Jikimoto T, Shirakawa T, Fujisawa M, Arakawa S. Comparison between phage-open-reading frame typing and automated repetitive-sequence-based PCR for typing MRSA isolates. *J Antibiot (Tokyo).* 2014 Aug;67(8):565-9.
108. Takei S, Omoto C, Kitagawa K, Morishita N, Katayama T, **Shigemura K**, Fujisawa M, Kawabata M, Hotta H, Shirakawa T. Oral administration of genetically modified *Bifidobacterium* displaying HCV-NS3 multi-epitope fusion protein could induce an HCV-NS3-specific systemic immune response in mice. *Vaccine.* 2014 May 23;32(25):3066-74.
109. Togo Y, Kubo T, Taoka R, Hiyama Y, Uehara T, Hashimoto J, Kurimura Y, Takahashi S, Tsukamoto T, Miyazaki J, Nishiyama H, Kira S, Kiyota H, Yazawa S, Niwa N, Hongo H, Oya M, Kato T, Yasuda M, Deguchi T, Ishikawa K, Hoshinaga K, Matsumoto M, **Shigemura K**, Tanaka K, Arakawa S, Fujisawa M, Wada K, Uehara S, Watanabe T, Kumon H, Kobayashi K, Matsubara A, Matsumoto M, Sho T, Hamasuna R, Matsumoto T, Hayami H, Nakagawa M, Yamamoto S. Occurrence of infection following prostate biopsy procedures in Japan: Japanese Research Group for Urinary Tract Infection (JRGU) - A multi-center retrospective study. *J Infect Chemother.* 2014 Apr;20(4):232-7.
110. Takaba K, **Shigemura K**, Osawa K, Nomi M, Fujisawa M, Arakawa S. Emergence of extended-spectrum β -lactamase-producing *Escherichia coli* in catheter-associated urinary tract infection in neurogenic bladder patients. *Am J Infect Control.* 2014 Mar;42(3):e29-31.

111. Tanaka K, **Shigemura K**, Ishimura T, Muramaki M, Miyake H, Fujisawa M. Evaluation of a 3D system based on a high-quality flat screen and polarized glasses for use by surgical assistants during robotic surgery. *Indian J Urol*. 2014 Jan;30(1):13-6.
112. Osawa K, **Shigemura K**, Abe Y, Jikimoto T, Yoshida H, Fujisawa M, Arakawa S. A case of nosocomial *Legionella pneumonia* associated with a contaminated hospital cooling tower. *J Infect Chemother*. 2014 Jan;20(1):68-70.
113. Osawa K, **Shigemura K**, Shimizu R, Kato A, Kimura M, Katayama Y, Okuya Y, Yutaka S, Nishimoto A, Kishi A, Fujiwara M, Yoshida H, Iijima Y, Fujisawa M, Shirakawa T. Antimicrobial resistance in *Salmonella* strains clinically isolated in Hyogo, Japan (2009-2012). *Jpn J Infect Dis*. 2014;67(1):54-7.
114. **Shigemura K**, Osawa K, Jikimoto T, Yoshida H, Hayama B, Ohji G, Iwata K, Fujisawa M, Arakawa S. Comparison of the clinical risk factors between *Candida albicans* and *Candida non-albicans* species for bloodstream infection. *J Antibiot (Tokyo)*. 2014 Apr;67(4):311-4
115. **Shigemura K**, Tanaka K, Arakawa S, Miyake H, Fujisawa M. Postoperative bacteriuria, pyuria and urinary tract infection in patients with an orthotopic sigmoid colon neobladder replacement. *J Antibiot (Tokyo)*. 2014 Feb;67(2):143-5.
116. Osawa K, Raharjo D, Wasito EB, Harijono S, **Shigemura K**, Osawa R, Sudarmo SM, Iijima Y, Shirakawa T. Frequency of diarrheagenic *Escherichia coli* among children in Surabaya, Indonesia. *Jpn J Infect Dis*. 2013;66(5):446-8.
117. Tanaka K, **Shigemura K**, Furukawa J, Ishimura T, Muramaki M, Miyake H, Fujisawa M. Comparison of the transperitoneal and retroperitoneal approach in robot-assisted partial nephrectomy in an initial case series in Japan. *J Endourol*. 2013 Nov;27(11):1384-8.
118. Togo Y, Taoka R, Yamamoto S, Hiyama Y, Uehara T, Hashimoto J, Kurimura Y, Takahashi S, Tsukamoto T, Miyazaki J, Nishiyama H, Kiyota H, Yazawa S, Oya M, Yasuda M, Deguchi T, Ishikawa K, Hoshinaga K, Matsumoto M, **Shigemura K**, Tanaka K, Arakawa S, Fujisawa M, Wada K, Uehara S, Watanabe T, Kumon H,

- Kobayashi K, Matsubara A, Matsumoto M, Sho T, Hamasuna R, Matsumoto T, Hayami H, Yamane T, Nakagawa M; Japanese Society of Urinary Tract Infection Cooperative Study Group.[A questionnaire survey of antimicrobial prophylaxis to prevent perioperative infection in urological field in Japan]. *Nihon Hinyokika Gakkai Zasshi*. 2013 Jul;104(4):579-88.
119. Behnsawy HM, **Shigemura K**, Meligy FY, Yamamichi F, Yamashita M, Haung WC, Li X, Miyake H, Tanaka K, Kawabata M, Shirakawa T, Fujisawa M. Possible role of sonic hedgehog and epithelial-mesenchymal transition in renal cell cancer progression. *Korean J Urol*. 2013 Aug;54(8):547-54.
120. Tanaka K, **Shigemura K**, Muramaki M, Takahashi S, Miyake H, Fujisawa M. Efficacy of using three-tesla magnetic resonance imaging diagnosis of capsule invasion for decision-making about neurovascular bundle preservation in robotic-assisted radical prostatectomy. *Korean J Urol*. 2013 Jul;54(7):437-41.
121. Osawa K, **Shigemura K**, Iguchi A, Shirai H, Imayama T, Seto K, Raharjo D, Fujisawa M, Osawa R, Shirakawa T. Modulation of O-antigen chain length by the wzz gene in Escherichia coli O157 influences its sensitivities to serum complement. *Microbiol Immunol*. 2013 Sep;57(9):616-23.
122. Osawa K, **Shigemura K**, Yoshida H, Fujisawa M, Arakawa S. Candida urinary tract infection and Candida species susceptibilities to antifungal agents. *J Antibiot (Tokyo)*. 2013 Nov;66(11):651-4.
123. **Shigemura K**, Tanaka K, Yamamichi F, Muramaki M, Arakawa S, Miyake H, Fujisawa M. Comparison of postoperative infection between robotic-assisted laparoscopic prostatectomy and open radical prostatectomy. *Urol Int*. 2014;92(1):15-9.
124. Taoka R, Togo Y, Kubo T, Kido M, Miki K, Kiyota H, Egawa S, Sugawara T, Yasuda M, Nakano M, Deguchi T, Nishino M, Ishikawa K, Shiroki R, Matsumoto M, **Shigemura K**, Tanaka K, Arakawa S, Fujisawa M, Wada K, Watanabe T, Kumon H, Kobayashi K, Matsubara A, Sho T, Hamasuna R, Matsumoto T, Hayami H, Nakagawa M, Yamamoto S. Assessment of antimicrobial prophylaxis to prevent

perioperative infection in patients undergoing prostate brachytherapy: multicenter cohort study. *J Infect Chemother*. 2013 Oct;19(5):926-30.

125. **Shigemura K**, Osawa K, Mukai A, Ohji G, Lee JJ, Yoshida H, Fujisawa M, Arakawa S. Infection control team activity and recent antibiograms in the Kobe University Hospital. *J Antibiot (Tokyo)*. 2013 Sep;66(9):511-6.
126. **Shigemura K**, Tanaka K, Osawa K, Arakawa S, Miyake H, Fujisawa M. Clinical factors associated with shock in bacteremic UTI. *Int Urol Nephrol*. 2013 Jun;45(3):653-7.
127. **Shigemura K**, Yamanaka N, Yamashita M. Can diffusion-weighted magnetic resonance imaging predict a high Gleason score of prostate cancer? *Korean J Urol*. 2013 Apr;54(4):234-8.
128. **Shigemura K**, Osawa K, Mukai A, Yoshida H, Fujisawa M, Arakawa S. Anti-MRSA drug use and antibiotic susceptibilities of MRSA at a university hospital in Japan from 2007 to 2011. *J Antibiot (Tokyo)*. 2013 May;66(5):273-6.
129. **Shigemura K**, Tanaka K, Haraguchi T, Yamamichi F, Muramaki M, Miyake H, Fujisawa M. Postoperative infectious complications in our early experience with holmium laser enucleation of the prostate for benign prostatic hyperplasia. *Korean J Urol*. 2013 Mar;54(3):189-93.
130. Yamamichi F, **Shigemura K**, Morishita S, Yamanaka K, Tanaka K, Miyake H, Fujisawa M. Significance of neoadjuvant hormonal therapy in radical retropubic prostatectomy: a retrospective single-surgeon study. *Yonsei Med J*. 2013 Mar 1;54(2):410-5.
131. Shirakawa T, Haraguchi T, **Shigemura K**, Morishita S, Minayoshi K, Miyazaki J, Yamada Y, Miyake H, Tanaka K, Fujisawa M. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. *Int J Urol*. 2013 Sep;20(9):903-10.

132. Matsumoto M, **Shigemura K**, Yamamichi F, Nakano Y, Miyake H, Tanaka K, Arakawa S, Fujisawa M.[A case of prostate abscess with sepsis, infectious endocarditis and pyogenic spondylitis]. *Hinyokika Kiyo*. 2012 Oct;58(10):565-8.
133. **Shigemura K**, Tanaka K, Yamamichi F, Shirakawa T, Miyake H, Fujisawa M. Does mutation in *gyrA* and/or *parC* or efflux pump expression play the main role in fluoroquinolone resistance in *Escherichia coli* urinary tract infections?: A statistical analysis study. *Int J Antimicrob Agents*. 2012 Dec;40(6):516-20.
134. Yasufuku T, **Shigemura K**, Tanaka K, Arakawa S, Miyake H, Fujisawa M. Risk factors for refractory febrile neutropenia in urological chemotherapy. *J Infect Chemother*. 2013 Apr;19(2):211-6.
135. Abe Y, **Shigemura K**, Yoshida H, Fujisawa M, Arakawa S. Risk factors for anti-MRSA drug resistance. *Int J Antimicrob Agents*. 2012 Nov;40(5):423-6.
136. Matsuoka T, **Shigemura K**, Yamamichi F, Fujisawa M, Kawabata M, Shirakawa T. Detection of tumor markers in prostate cancer and comparison of sensitivity between real time and nested PCR. *Kobe J Med Sci*. 2012 Jun 27;58(2):E51-9.
137. Yamamichi F, Matsuoka T, **Shigemura K**, Kawabata M, Shirakawa T, Fujisawa M. Potential establishment of lung metastatic xenograft model of androgen receptor-positive and androgen-independent prostate cancer (C4-2B). *Urology*. 2012 Oct;80(4):951.e1-7.
138. Matsumoto M, **Shigemura K**, Shirakawa T, Nakano Y, Miyake H, Tanaka K, Kinoshita S, Arakawa S, Kawabata M, Fujisawa M. Mutations in the *gyrA* and *parC* genes and in vitro activities of fluoroquinolones in 114 clinical isolates of *Pseudomonas aeruginosa* derived from urinary tract infections and their rapid detection by denaturing high-performance liquid chromatography. *Int J Antimicrob Agents*. 2012 Nov;40(5):440-4.
139. **Shigemura K**, Yamanaka N, Yamashita M. Veil nerve-sparing technique and postoperative urinary continence in open antegrade radical prostatectomy. *Urol Int*. 2012;89(3):283-9.

140. Meligy FY, **Shigemura K**, Behnsawy HM, Fujisawa M, Kawabata M, Shirakawa T. The efficiency of in vitro isolation and myogenic differentiation of MSCs derived from adipose connective tissue, bone marrow, and skeletal muscle tissue. *In Vitro Cell Dev Biol Anim.* 2012 Apr;48(4):203-15.
141. **Shigemura K**, Motoyama S, Yamashita M. Do additional cores from MRI cancer-suspicious lesions to systematic 12-core transrectal prostate biopsy give better cancer detection? *Urol Int.* 2012;88(2):145-9.
142. **Shigemura K**, Tanaka K, Matsumoto M, Nakano Y, Shirakawa T, Miyata M, Yamashita M, Arakawa S, Fujisawa M. Post-operative infection and prophylactic antibiotic administration after radical cystectomy with orthotopic neobladder urinary diversion. *J Infect Chemother.* 2012 Aug;18(4):479-84.
143. Yamamichi F, **Shigemura K**, Matsumoto M, Nakano Y, Tanaka K, Arakawa S, Fujisawa M. Relationship between urinary tract infection categorization and pathogens' antimicrobial susceptibilities. *Urol Int.* 2012;88(2):198-208.
144. Adhim Z, Lin X, Huang W, Morishita N, Nakamura T, Yasui H, Otsuki N, **Shigemura K**, Fujisawa M, Nibu K, Shirakawa T. E10A, an adenovirus-carrying endostatin gene, dramatically increased the tumor drug concentration of metronomic chemotherapy with low-dose cisplatin in a xenograft mouse model for head and neck squamous-cell carcinoma. *Cancer Gene Ther.* 2012 Feb;19(2):144-52.
145. Matsumoto M, **Shigemura K**, Yamamichi F, Tanaka K, Nakano Y, Arakawa S, Fujisawa M. Prevention of infectious complication and its risk factors after urological procedures of the upper urinary tract. *Urol Int.* 2012;88(1):43-7.
146. **Shigemura K**, Yamanaka N, Imanishi O, Yamashita M. Wallace direct versus anti-reflux Le Duc ureteroileal anastomosis: comparative analysis in modified Studer orthotopic neobladder reconstruction. *Int J Urol.* 2012 Jan;19(1):49-53.
147. Tanaka K, Arakawa S, Miura T, **Shigemura K**, Nakano Y, Takahashi S, Tsukamoto T, Matsumoto T, Fujisawa M. Analysis of isolated bacteria and short-term antimicrobial prophylaxis with tazobactam-piperacillin (1:4 ratio) for

prevention of postoperative infections after radical cystectomy. *J Infect Chemother*. 2012 Apr;18(2):175-9.

148. **Shigemura K**, Yasufuku T, Yamanaka K, Yamahsita M, Arakawa S, Fujisawa M. How long should double J stent be kept in after ureteroscopic lithotripsy? *Urol Res*. 2012 Aug;40(4):373-6.
149. **SHIGEMURA K**, YAMAMICHI F, MATSUMOTO M, TANAKA K, YAMASHITA M, ARAKAWA S, and FUJISAWA M. Comparison of Naftopidil 75 mg with Tamsulosin Hydrochloride 0.2 mg in the Treatment of Lower Urinary Tract Symptoms with Benign Prostatic Hyperplasia LUTS: Lower Urinary Tract Symptoms Volume 4, Issue 3, pages 136–139, September 2012
150. Yasufuku T, **Shigemura K**, Shirakawa T, Matsumoto M, Nakano Y, Tanaka K, Arakawa S, Kawabata M, Fujisawa M. Mechanisms of and risk factors for fluoroquinolone resistance in clinical *Enterococcus faecalis* isolates from patients with urinary tract infections. *J Clin Microbiol*. 2011 Nov;49(11):3912-6.
151. Adhim Z, Matsuoka T, Bito T, **Shigemura K**, Lee KM, Kawabata M, Fujisawa M, Nibu K, Shirakawa T. In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines. *Br J Cancer*. 2011 Jul 26;105(3):393-402.
152. **Shigemura K**, Matsumoto M, Tanaka K, Yamashita M, Arakawa S, Fujisawa M. Efficacy of combination use of Beta-lactamase inhibitor with penicillin and fluoroquinolones for antibiotic prophylaxis in transrectal prostate biopsy. *Korean J Urol*. 2011 Apr;52(4):289-92.
153. **Shigemura K**, Huang WC, Li X, Zhau HE, Zhu G, Gotoh A, Fujisawa M, Xie J, Marshall FF, Chung LW. Active sonic hedgehog signaling between androgen independent human prostate cancer cells and normal/benign but not cancer-associated prostate stromal cells. *Prostate*. 2011 Dec;71(16):1711-22.
154. **Shigemura K**, Tanaka K, Adachi M, Yamashita M, Arakawa S, Fujisawa M. Chronological change of antibiotic use and antibiotic resistance in *Escherichia coli* causing urinary tract infections. *J Infect Chemother*. 2011 Oct;17(5):646-51.

155. Matsumoto M, **Shigemura K**, Yamanaka K, Arakawa S, Fujisawa M.
[Bladder stone formation following radical retropubic prostatectomy: a report of 2 cases]. *Hinyokika Kiyo*. 2011 Feb;57(2):91-3.
156. Minori Matsumoto, **Katsumi Shigemura**, Masato Fujisawa. Spontaneous Rupture of Adrenal Myelolipoma. *UroToday Int J*. 2011 Oct;4(5):art 55
157. Matsumoto M, **Shigemura K**, Yamamichi F, Nakano Y, Tanaka K, Arakawa S, Fujisawa M. Prophylactic antibiotic administration for prevention of surgical site infection in urological laparoscopic surgeries. *Kobe J Med Sci*. 2012 May 24;57(4):E137-44.
158. **Shigemura K**, Yasufuku T, Yamashita M, Arakawa S, Fujisawa M. Efficacy of combining flexible and rigid ureteroscopy for transurethral lithotripsy. *Kobe J Med Sci*. 2010 Aug 23;56(1):E24-8.
159. **Shigemura K**, Yasufuku T, Yamanaka K, Yamashita M, Uefuji T, Arakawa S, Fujisawa M. Limited hydration may reduce intraoperative blood loss in retropubic radical prostatectomy. *Kobe J Med Sci*. 2010 Aug 20;56(1):E18-23.
160. Yasufuku T, **Shigemura K**, Shirakawa T, Matsumoto M, Nakano Y, Tanaka K, Arakawa S, Kinoshita S, Kawabata M, Fujisawa M. Correlation of overexpression of efflux pump genes with antibiotic resistance in *Escherichia coli* Strains clinically isolated from urinary tract infection patients. *J Clin Microbiol*. 2011 Jan;49(1):189-94.
161. Yasufuku T, **Shigemura K**, Shirakawa T, Nakano Y, Tanaka K, Arakawa S, Kinoshita S, Nishimura K, Kawabata M, Fujisawa M. Risk factors and mechanisms of fluoroquinolone resistance in 156 *Escherichia coli* strains clinically isolated from urinary tract infections. *Scand J Infect Dis*. 2011 Feb;43(2):83-8.
162. **Shigemura K**, Yasufuku T, Arakawa S, Yamashita M, Fujisawa M. Efficacy of early use of snake retractor in retroperitoneoscopic nephrectomy or nephroureterectomy. *J Endourol*. 2010 Nov;24(11):1771-4.

163. Yasufuku T, **Shigemura K**, Yamashita M, Arakawa S, Fujisawa M. Selection of first-line i.v. antibiotics for acute pyelonephritis in patients requiring emergency hospital admission. *J Infect Chemother*. 2011 Apr;17(2):231-7.
164. Yasufuku T, **Shigemura K**, Matsumoto O, Arakawa S, Fujisawa M. Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer. *J Infect Chemother*. 2010 Jun;16(3):200-5.
165. **Shigemura K**, Fujisawa M, et al. Is the Transitional Zone Biopsy Specimen Significant for Prostate Cancer Detection? *UroToday Int J*. 2010 Apr;3(2).
166. **Shigemura K**, Arakawa S, Yamashita M, Yasufuku T, Fujisawa M. Surgical site infections may be reduced by shorter duration of prophylactic antibiotic medication in urological surgeries. *Jpn J Infect Dis*. 2009 Nov;62(6):440-3.
167. **Shigemura K**, Yasufuku T, Yamashita M, Arakawa S, Fujisawa M. Prophylactic use of isepamicin and levofloxacin for transrectal prostate biopsy: a retrospective single center study. *Int J Urol*. 2009 Sep;16(9):723-5.
168. Yasufuku T, **Shigemura K**, Tanaka H, Matsumoto O, Nakano Y, Tanaka K, Fujisawa M. [Carcinomatous meningitis from prostate cancer diagnosed by cerebrospinal fluid cytology and magnetic resonance image: a case report and review of the literature]. *Hinyokika Kiyo*. 2009 Jun;55(6):361-5.
169. Yasufuku T, **Shigemura K**, Tanaka H, Matsumoto O, Fujisawa M. [Traumatic urethral disruption treated by endoscopic management with transluminal puncture under fluoroscopic guidance: a case report and review of the literature]. *Hinyokika Kiyo*. 2009 May;55(5):271-5.
170. **Shigemura K**, Yasufuku T, Yamashita M, Arakawa S, Fujisawa M. Bilateral emphysematous pyelonephritis cured by antibiotics alone: a case and literature review. *Jpn J Infect Dis*. 2009 May;62(3):206-8.
171. Yasufuku T, **Shigemura K**, Fujisawa M. Mucinous tubular and spindle cell carcinoma. *Int J Urol*. 2009 Apr;16(4):425-6.

172. **Shigemura K**, Arakawa S, Tanaka K, Fujisawa M. Clinical investigation of isolated bacteria from urinary tracts of hospitalized patients and their susceptibilities to antibiotics. *J Infect Chemother*. 2009 Feb;15(1):18-22.
173. **Shigemura K**, Isotani S, Wang R, Fujisawa M, Gotoh A, Marshall FF, Zhau HE, Chung LW. Soluble factors derived from stroma activated androgen receptor phosphorylation in human prostate LNCaP cells: roles of ERK/MAP kinase. *Prostate*. 2009 Jun 15;69(9):949-55.
174. **Shigemura K**, Arakawa S, Miura T, Yasufuku T, Nakano Y, Tanaka K, Fujisawa M. Retroperitoneal abscess perforating into the thoracic cavity in an immunocompromised host. *J Infect Chemother*. 2008 Aug;14(4):305-7.
175. **Shigemura K**, Arakawa S, Miura T, Nakano Y, Tanaka K, Fujisawa M. Significance of fluoroquinolone-resistant *Escherichia coli* in urinary tract infections. *Jpn J Infect Dis*. 2008 May;61(3):226-8.
176. Miura T, Tanaka K, **Shigemura K**, Nakano Y, Takenaka A, Fujisawa M. Levofloxacin resistant *Escherichia coli* sepsis following an ultrasound-guided transrectal prostate biopsy: report of four cases and review of the literature. *Int J Urol*. 2008 May;15(5):457-9.
177. Okamoto A, Shirakawa T, Bito T, **Shigemura K**, Hamada K, Gotoh A, Fujisawa M, Kawabata M. Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo. *Urology*. 2008 Jan;71(1):156-60.
178. **Shigemura K**, Tanaka K, Miura T, Nakano Y, Arakawa S, Fujisawa M. PET-positive pheochromocytoma in the staging of malignant myxofibrosarcoma *European Journal of Radiology Extra*, Volume 67, Issue 2, August 2008, Pages e79-e81
179. Arakawa S, Tanaka K, Miura T, **Shigemura K**, Takenaka A, Matsui T, Kamidono S, Nakano Y, Fujisawa M. Usefulness and problems of the urinary tract infection criteria for evaluating drug efficacy for complicated urinary tract infections. *J Infect Chemother*. 2007 Oct;13(5):279-84.

180. **Shigemura K**, Arakawa S, Yamanaka K, Kataoka N, Yuien K, Fujisawa M. Significance of lateral biopsy specimens during transrectal ultrasound-guided prostate biopsies in Japanese men. *Int J Urol*. 2007 Oct;14(10):935-8.
181. **Shigemura K**, Arakawa S, Yamanaka K, Yasui N, Matsubara S, Iwamoto T, Kataoka N, Yuien K, Fujisawa M. Potential predictive factors of positive prostate biopsy in the Japanese population. *Int Urol Nephrol*. 2008;40(1):91-6.
182. **Shigemura K**, Arakawa S, Yuen K, Kataoka N, Fujisawa M. Clinical trial for preoperative diagnosis of locally advanced invasive ureteral cancer. *Kobe J Med Sci*. 2007;53(1-2):71-7.
183. **Shigemura K**, Sung SY, Kubo H, Arnold RS, Fujisawa M, Gotoh A, Zhau HE, Chung LW. Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells. *Prostate*. 2007 May 15;67(7):722-31.
184. **Shigemura K**, Arbiser JL, Sun SY, Zayzafoon M, Johnstone PA, Fujisawa M, Gotoh A, Weksler B, Zhau HE, Chung LW. Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. *Cancer*. 2007 Apr 1;109(7):1279-89.
185. **Shigemura K**, Tanaka K, Arakawa S, Hara I, Kawabata G, Fujisawa M. Malignant pheochromocytoma with IVC thrombus. *Int Urol Nephrol*. 2007;39(1):103-6.
186. Arakawa S, Nakano Y, Miura T, **Shigemura K**, Tanaka K, Fujisawa M. Clinical study of complicated urinary tract infection using 'The UTI Criteria (Draft Fourth Edition)': measurement methods for pyuria. *Int J Urol*. 2006 Dec;13(12):1484-7.
187. Chung LW, Huang WC, Sung SY, Wu D, Odero-Marah V, Nomura T, **Shigemura K**, Miyagi T, Seo S, Shi C, Moliterno J, Elmore J, Anderson C, Isotani S, Edlund M, Hsieh CL, Wang R, Shehata B, Zhau HE. Stromal-epithelial interaction in prostate cancer progression. *Clin Genitourin Cancer*. 2006 Sep;5(2):162-70.

188. Sung SY, Kubo H, **Shigemura K**, Arnold RS, Logani S, Wang R, Konaka H, Nakagawa M, Mousses S, Amin M, Anderson C, Johnstone P, Petros JA, Marshall FF, Zhau HE, Chung LW. Oxidative stress induces ADAM9 protein expression in human prostate cancer cells. *Cancer Res.* 2006 Oct 1;66(19):9519-26.
189. **Shigemura K**, Arakawa S, Yuen K, Kataoka N, Fujisawa M. [A case of ureteral carcinoma at 11 years after radical cystectomy and rectal bladder reconstruction: a case report]. *Hinyokika Kyo.* 2006 Aug;52(8):637-40.
190. **Shigemura K**, Tanaka K, Hara I, Muramaki M, Arakawa S, Fujisawa M. Clinical study for management of supportive treatment for high-dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) for intractable testicular tumor. *Hinyokika Kyo.* 2006 Jul;52(7):531-6.
191. **Shigemura K**, Arakawa S, Kamidono S, Nakano Y, Fujisawa M. Effect of sildenafil on arterial stiffness, as assessed by pulse wave velocity, in patients with erectile dysfunction. *Int J Urol.* 2006 Jul;13(7):956-9.
192. **Shigemura K**, Arakawa S, Sakai Y, Kinoshita S, Tanaka K, Fujisawa M. Complicated urinary tract infection caused by *Pseudomonas aeruginosa* in a single institution (1999-2003). *Int J Urol.* 2006 May;13(5):538-42.
193. **Shigemura K**, Arakawa S, Nakano Y, Hara I, Tanaka K, Fujisawa M. Larger prostate causes higher frequency of infectious complications in prostate biopsy. *Urol Int.* 2006;76(4):321-6.
194. **Shigemura K**, Shirakawa T, Tanaka K, Arakawa S, Gotoh A, Fujisawa M. Rapid detection of the fluoroquinolone resistance-associated ParC mutation in *Neisseria gonorrhoeae* using TaqMan probes. *Int J Urol.* 2006 Mar;13(3):277-81.
195. **Shigemura K**, Shirakawa T, Wada Y, Kamidono S, Fujisawa M, Gotoh A. Antitumor effects of etodolac, a selective cyclooxygenase-II inhibitor, against human prostate cancer cell lines in vitro and in vivo. *Urology.* 2005 Dec;66(6):1239-44.

196. **Shigemura K**, Shirakawa T, Massi N, Tanaka K, Arakawa S, Gotoh A, Fujisawa M. Presence of a mutation in *ponA1* of *Neisseria gonorrhoeae* in numerous clinical samples resistant to various beta-lactams and other, structurally unrelated, antimicrobials. *J Infect Chemother*. 2005 Oct;11(5):226-30.
197. **Shigemura K**, Tanaka K, Yasuda M, Ishihara S, Muratani T, Deguchi T, Matsumoto T, Kamidono S, Nakano Y, Arakawa S, Fujisawa M. Efficacy of 1-day prophylaxis medication with fluoroquinolone for prostate biopsy. *World J Urol*. 2005 Nov;23(5):356-60.
198. **Shigemura K**, Tanaka K, Okada H, Nakano Y, Kinoshita S, Gotoh A, Arakawa S, Fujisawa M. Pathogen occurrence and antimicrobial susceptibility of urinary tract infection cases during a 20-year period (1983-2002) at a single institution in Japan. *Jpn J Infect Dis*. 2005 Oct;58(5):303-8.
199. Hinata N, Shirakawa T, Okada H, **Shigemura K**, Kamidono S, Gotoh A. Quantitative detection of *Escherichia coli* from urine of patients with bacteriuria by real-time PCR. *Mol Diagn*. 2004;8(3):179-84.
200. **Shigemura K**, Shirakawa T, Okada H, Tanaka K, Kamidono S, Arakawa S, Gotoh A. Rapid detection and differentiation of Gram-negative and Gram-positive pathogenic bacteria in urine using TaqMan probe. *Clin Exp Med*. 2005 Mar;4(4):196-201.
201. **Shigemura K**, Shirakawa T, Okada H, Tanaka K, Udaka T, Kamidono S, Arakawa S, Gotoh A. Rapid detection of *gyrA* and *parC* mutations in fluoroquinolone-resistant *Neisseria gonorrhoeae* by denaturing high-performance liquid chromatography. *J Microbiol Methods*. 2004 Dec;59(3):415-21.
202. **Shigemura K**, Shirakawa T, Okada H, Hinata N, Acharya B, Kinoshita S, Kofuku T, Kawabata M, Kamidono S, Arakawa S, Gotoh A. Mutations in the *gyrA* and *parC* genes and in vitro activities of fluoroquinolones in 91 clinical isolates of *Neisseria gonorrhoeae* in Japan. *Sex Transm Dis*. 2004 Mar;31(3):180-4.
203. **Shigemura K**, Okada H, Shirakawa T, Tanaka K, Arakawa S, Kinoshita S, Gotoh A, Kamidono S. Susceptibilities of *Neisseria gonorrhoeae* to fluoroquinolones and

other antimicrobial agents in Hyogo and Osaka, Japan. Sex Transm Infect. 2004 Apr;80(2):105-7.

204. **Shigemura K**, Yuen K, Kataoka N, Iwamoto T. [A case of foreign body in the urinary bladder--chewing gum found in urinary bladder]. Hinyokika Kiyo. 2002 Apr;48(4):229-30.

Topic: Collaboration between TMU and Kobe University

Speaker: Katsumi Shigemura



Mr. Anthony Nguyen graduated from Indiana University, Bloomington, with a bachelor's degree in economics and began his career as a Financial Advisor at the Morgan Stanley Beverly Hills office. He later moved on to join Merrill Lynch's global private client group. In 2010, Mr Anthony relocated to Busan South Korea and began working for Dong-A University Hospital's Global Center of Excellence in Clinical Trials, as the Director of Strategic Planning and Communications. He is one of the founding members of REACTA. Currently, he resides on the island of Oahu and is the principal consultant for Dong-A University Hospital's Clinical Trial Center. Outside of work, he enjoys judo, hiking and deep-sea diving with his wife and three children.

Topic: The importance of collaboration and the future of the REACTA.

Speaker: Anthony Va Nguyen

	Name:	Min-Huei (Marc) Hsu
Title:	1. Director/Professor 2. Consultant neurosurgeon 3. Chief Data Officer	
Institution:	1. Graduate Institute of Data Science, Taipei Medical University 2. Shuang-Ho Hospital, Taipei Medical University 3. Taipei Medical University	
Research Areas:	<ul style="list-style-type: none"> • Health IT • Data Management • AI Application in Healthcare 	
Education:	1.M.D. School of Medicine, Taipei Medical University 2.M.Sc. Graduate Institute of Medical Informatics, Taipei Medical University 3.Ph.D. Graduate Institute of Medical Science, Taipei Medical University	
Experiences:	Dr. Min-Huei Hsu was appointed as Director of Medical Informatics Center at Ministry of Health and Welfare of Taiwan in March 2011. Prior to the MOHW appointment, Dr. Hsu served as CIO at Taipei Medical University and also a Consultant Neurosurgeon at Wanfang Hospital (a 746-bed hospital affiliated to Taipei Medical University). In addition, he is author and co-author of more than 60 papers and articles in international conferences and scientific journals, focusing on health data, health information technology, e-health, electronic medical record system, hospital information management and patient safety.	

Topic: Collaboration with office of Data Science.

Speaker: Min-Huei Hsu

CHUN (AUSTIN) CHANGOU

CURRICULUM VITAE

Email austinc99@tmu.edu.tw

Mobile +886 978008895

Personal Statement

Chun (Austin) Changou, a molecular biologist and geneticist, who is familiar with bacteria, yeast, drosophila, murine and mammalian cell models, has been studying the structure and mechanism of Autophagy in cancer development. His past experience has led him through many different types of optical technologies, ranging from Spectral Karyotyping (SKY), Spinning-disk confocal, deconvolution, structural illumination (SIM), transmission electron microscopy (TEM), cryogenic transmission electron microscopy (Cryo-EM), and mass spectrometry imaging. His early research includes the characterization of autophagosome and lysosome during nutrient starvation with advanced fluorescence microscopy and electron microscopy. Later he identifies the cellular fate of prolonged autophagy, and resolves the conflict nature of dual role of autophagy in cancer cells. More importantly, his findings also establish the foundation of metabolic therapy, by removing semi-essential amino acid arginine, in battling prostate cancer. His work and associated methods have been published in PNAS, Autophagy, and Journal of Visualized Experiment.

He has demonstrated accomplishments in both leadership and management skill. Since his appointment as Director of Core Facility Center (CFC) at Taipei Medical University (TMU) in 2015, he has been working tirelessly to strengthen the connection between research faculties and CFC, as well as organizing a well-trained core team to resolve difficult research-related questions and tasks. He setup seven specialty cores, (namely Imaging Core, Mass Spec. Core, Flow Cytometry Core, NMR Core, and Bioinformatics Core), and designs a top-notch mass spectrometry core 2.0 and natural compound isolation core. In 2021, the completion of Single Cell Genomics Core, which marks another milestone in TMU history, successfully connects bedside from bench-side, and provides advanced scientific services to the university and TMU health system. All of which have been evaluated as critical assets by the TMU research community. He also systematically connects the characteristic features of each individual specialty core to match the needs and produce insightful and innovative results for the research teams at TMU. In 2016, he was appointed as Director of Biomedical Mass Spec. Core, where he leads a small team to resurrect a top-notch Time-of-Flight Secondary Ion Mass Spec (ToF-SIMS). After years of hard working, with collaborations worldwide, his ToF-SIMS team can now generate reliable, reproducible, and high-resolution mass spec. images, and thus contribute to several high-impact research papers. His team continues to strive for better representation of mass spec. imaging ever since. Austin is a strong believer in education and hands-on training. By teaming up with different colleges at TMU, he has translated CFC strength into graduate level learning opportunities, where students can thoroughly experience advanced technologies and broaden their research horizon.

Positions and Employment

2016 – present	Director	Biomedical Mass Spec. Core, Taipei Medical University, Taiwan.
2015 – present	Consultant	Biomedical Research Division, Shuang-Ho Hospital, Taiwan.
2015 – present	Director	Core Facility Center, Taipei Medical University, Taiwan.
2014 – 2015	Senior Technical Specialist	HJ Kung Lab, Taipei Medical University, Taiwan.
2009 – 2014	Senior Research Specialist	HJ Kung Lab, University of California, Davis, CA.
2005 – 2007	PhD. Program	JR Pringle Lab, Stanford University, Palo Alto, CA.
2002 – 2005	PhD. Program	JR Pringle Lab, University of North Carolina at Chapel Hill, NC.
2001	Special Training	T Ried Lab, National Cancer Institute, NIH, Bethesda, MD.
2000 – 2002	Senior Research Assistant	PP Pandolfi Lab, Memorial Sloan-Kettering Cancer Center, New York.

Synergistic Activities

- **Establish Single Cell Genomics Core (2021)** Design, organize, execute and oversee the core construction. Setup technical staff training protocol, standard operation procedure, user guideline, and associated business model.
- **Establish Compound Isolation Core (2018)** Design, organize, execute and oversee the core construction. Setup standard operation procedure and user guideline.
- **Establish Mass Spec. Core 2.0. (2016 - 2017)** Design, organize, execute, and oversee the Mass Spec. Core 2.0 construction. Setup technical staff training protocol, graduate level technical training course, standard operating procedure, user guideline, and business model.
- **Biomedical Mass Spec. Imaging Core overhaul. (2016 – present)** Assemble and train a technical team. Setup collaborations worldwide. Setup standard operating procedure, user guideline, and associated business model.
- **TMU Core Facility Center reorganization. (2015 - 2017)** Centralize TMU research equipment. Setup 5 independent specialty cores (Imaging, Mass Spec., Flow Cytometry, NMR, and Bioinformatics Cores) and associated business and operation models.
- **British FutureLearn Massive Online Open Course (MOOC). (2015)** Design, organize, and execute the MOOC education program with TMU Ph.D. Program for Translational Medicine (<https://www.futurelearn.com/courses/translational-research>).
- **University of California at Davis, Medical Center, Center for Biophotonics Science & Technology (CBST). (2013)** NIH Bio-Technology Resource Center (BTRC) Grant Proposal and Site Review: represent TR&D Team 3: Tools to enable virtual multimodality.
- **University of California at Davis, Comprehensive Cancer Center Annual Cancer Research Symposium. (2012)** “Microscopic analysis of cell death by metabolic stress induced autophagy in prostate cancer”, Rank #1.
- **Innovative Minds in Prostate Cancer Today (IMPACT). (2006)** “Metabolic stress induces autophagy and caspase-independent cell death in prostate cancer”.
- **Intel Science Talent Search (formally known as Westinghouse STS).** Mentor of Selena Li, Winner of 5th place in Intel STS competition nationwide U.S.A. (2011).

Lecture

- “Mapping the Uncharted Territory”, Special Lecture, Taipei Medical University. (2016 - 2021)
- “Mass Spec. and Metabolism Studies, Analysis and Application”, Special Lecture, Shuang-Ho Hospital. (2017)
- “Mass Spec. and You, using M.S. to Visualize Signals”, Faculty Research Seminar, TMU. (2016 - 2018)
- “Advanced Microscopy in Cancer Study”, Guest Lecture, University of California at Davis. (2011)

Publications

1. **Changou CA**, Shiah HS, Chen LT, Liu S, Luh F, Liu SH, Cheng YC, Yen Y. A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma. *Oncologist*. 2021 Mar;26(3):e367-e373.
2. Huang TY, Chang TC, Chin YT, Pan YS, Chang WJ, Liu FC, Hastuti ED, Chiu SJ, Wang SH, **Changou CA**, Li ZL, Chen YR, Chu HR, Shih YJ, Cheng RH, Wu A, Lin HY, Wang K, Whang-Peng J, Mousa SA, Davis PJ. NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer. *Cells*. 2020 Aug 3;9(8):1830.
3. Chang CC, Huang YS, Lin YM, Lin CJ, Jeng JC, Liu SM, Ho TL, Chang RT, **Changou CA**, Ho CC, Shih HM. Author Correction: The role of sentrin-specific protease 2 substrate recognition in TGF- β -induced tumorigenesis. *Sci Rep*. 2020 Jun 4;10(1):9350.
4. Cheng TM, Li R, Kao YJ, Hsu CH, Chu HL, Lu KY, **Changou CA**, Chang CC, Chang LH, Tsai ML, and Mi FL. Synthesis and characterization of Gd-DTPA/fucoidan/peptide complex nanoparticle and in vitro magnetic resonance imaging of inflamed endothelial cells. *Mater Sci Eng C Mater Biol Appl*. 2020 Sep;114:111064.
5. Wu YW, Huang CC, **Changou CA**, Lu LS, Goubran H, Burnouf T. Clinical-grade cryopreserved doxorubicin-loaded platelets: role of cancer cells and platelet extracellular vesicles activation loop. *J Biomed Sci*. 2020 Mar 23;27(1):45.
6. Wu KS, Ho DM, Jou ST, Yu AL, Tran HM, Liang ML, Chen HH, Lee YY, Chen YW, Lin SC, Chang FC, Tsai ML, Liu YL, Lee HL, Hsieh KL, Huang WC, Sung SY, Chang CC, **Changou CA**, Liang KH, Hsieh TH, Liu YR, Chao ME, Chen W, Chu SS, Cho EC, Wong TT. Molecular-Clinical Correlation in Pediatric Medulloblastoma: A Cohort Series Study of 52 Cases in Taiwan. *Cancers (Basel)*. 2020 Mar 11;12(3):653.
7. Tran HM, Wu KS, Sung SY, **Changou CA**, Hsieh TH, Liu YR, Liu YL, Tsai ML, Lee HL, Hsieh KL, Huang WC, Liang ML, Chen HH, Lee YY, Lin SC, Ho DM, Chang FC, Chao ME, Chen W, Chu SS, Yu AL, Yen Y, Chang CC, Wong TT. Upregulation of Protein Synthesis and Proteasome Degradation Confers Sensitivity to Proteasome Inhibitor Bortezomib in Myc-Atypical Teratoid/Rhabdoid Tumors. *Cancers (Basel)*. 2020 Mar 22;12(3):752.
8. Wu YW, Huang CC, **Changou CA**, Lu LS, Goubran H, and Burnouf T. Clinical-grade cryopreserved doxorubicin-loaded platelets: role of cancer cells and platelet extracellular vesicles activation loop. *J Biomed Sci*. 2020 Mar 23;27(1):45.
9. Ho Y, Wu CY, Chin YT, Li ZL, Pan YS, Huang TY, Su PY, Lee SY, Crawford DR, Su KW, Chiu HC, Shih YJ, **Changou CA**, Yang YSH, Whang-Peng J, Chen YR, Lin HY, Mousa SA, Davis PJ, Wang K. NDAT suppresses pro-inflammatory gene expression to enhance resveratrol-induced anti-proliferation in oral cancer cells. *Food Chem Toxicol*. 2020 Feb;136:111092.
10. Chen YR, Chen YS, Chin YT, Li ZL, Shih YJ, Yang YSH, **Changou CA**, Su PY, Wang SH, Wu YH, Chiu HC, Lee SY, Liu LF, Whang-Peng J, Lin HY, Mousa SA, Davis PJ, Wang K. Thyroid hormone-induced expression of inflammatory cytokines interfere with resveratrol-induced anti-proliferation of oral cancer cells. *Food Chem Toxicol*. 2019 Oct;132:110693.
11. Chen YF, Wang YH, Lei CS, **Changou CA**, Davis ME, Yen Y. Host immune response to anti-cancer camptothecin conjugated cyclodextrin-based polymers. *J Biomed Sci*. 2019 Oct 23;26(1):85.
12. Jassey A, Liu CH, Changou CA, Richardson CD, Hsu HY, Lin LT. Hepatitis C Virus Non-Structural Protein 5A (NS5A) Disrupts Mitochondrial Dynamics and Induces Mitophagy. *Cells*. 2019 Mar 29;8(4):290.
13. Chen WT, Hsu WT, Yen MH, **Changou CA**, Han CL, Chen YJ, Cheng JY, Chang TH, Lee OK, Ho JH. Alteration of mesenchymal stem cells polarity by laminar shear stimulation promoting β -catenin nuclear localization. *Biomaterials*. 2019 Jan;190-191:1-10.

14. Chang, T.C., Chin, Y.T., Nana, A.W., Wang, S.H., Liao, Y.M., Chen, Y.R., Shih, Y.J., **Changou, C.A.**, Yang, Y.S., Wang, K., Whang-Peng, J., Wang, L.S., Stain, S.C., Shih, A., Lin, H.Y., Wu, C.H., and Davis, P.J. "Enhancement by Nano-Diamino Tetrac of antiproliferative action of Gefitinib on colorectal cancer cells: mediation by EGFR sialylation and PI3K activation" 2018 *Horm. Cancer*.
15. Ho, Y., Yang, Y.C., Chin, Y.T., Chou, S.Y., Chen, Y.R., Shih, Y.J., Whang-Peng, J., **Changou, C.A.**, Liu, H.L., Lin, S.J., Tang, H.Y., Lin, H.Y., Davis, P.J. "Resveratrol inhibits human leiomyoma cell proliferation via crosstalk between integrin $\alpha\upsilon\beta 3$ and IGF-1R" 2018 *Food Che Toxicol*.
16. Chang, C.C., Huang, Y.S., Lin, Y.M., Lin, C.J., Jeng, J.C., Liu, S.M., Ho, T.L., Chang, R.T., **Changou, C.A.**, Ho, C.C., Shih, H.M. "The role of sentrin-specific protease 2 substrate recognition in TGF- β -induced tumorigenesis" 2018 *Sci Rep*.
17. Chin, Y.T., Wei, P.L., Ho, Y., Nana, A.W., **Changou, C.A.**, Chen, Y.R., Yang, Y.S., Hsieh, M.T., Hercbergs, A., Davis, P.J., Shih, Y.J., Lin, H.Y. "Thyroxine inhibits resveratrol-caused apoptosis by PD-L1 in ovarian cancer cells" 2018 *Endocr Relat Cancer*.
18. Wang, K.H., Wang, Y.M., Chiu, L.H., Chen, T.C., Tsai, Y.H., Zuo, C.S., Chen, K.C., **Changou, C.A.**, Lai, W.T. "Optical imaging of ovarian cancer using a matrix metalloproteinase-3-sensitive near-infrared fluorescent probe" 2018 *PLoS One*.
19. **Changou, C.A.**, Ajoy, R., Chou, S.Y. "Live images of GLUT4 protein trafficking in mouse primary hypothalamic neurons using deconvolution microscopy" 2017 *J Vis Exp*.
20. Nana, A.W., Chin, Y.T., Lin, C.Y., Ho, Y., Bennett, J.A., Shih, Y.J., Chen, Y.R., **Changou, C.A.**, Pedersen, J.Z., Incerpi, S., Liu, L.F., Whang-Peng, J., Fu, E., Li, W.S., Mousa, S.A., Lin, H.Y., Davis, P.J. "Tetrac downregulates β -catenin and HMGA2 to promote the effect of resveratrol in colon cancer" 2018 *Endocr Relat Cancer*.
21. Chen, C.H., **Changou, C.A.**, Hsieh, T.H., Lee, Y.C., Chu, C.Y., Hsu, K.C., Wang, H.C., Lin, Y.C., Lo, Y.N., Liu, Y, R., Liou, J.P., Yen, Y. "Dual inhibition of PIK3C3 and FGFR as a new therapeutic approach to treat bladder cancer" 2018 *Clin Cancer Res*.
22. Chiang, W.F., Cheng, T.M., Chang, C.C., Pan, S.H., **Changou, C.A.**, Chang, T.H., Lee, K.H., Wu, S.Y., Chen, Y.F., Chuang, K.H., Shieh, D.B., Chen, Y.L., Tu, C.C., Tsui, W.L., Wu, M.H. "Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) promotes EGF receptor signaling of oral squamous cell carcinoma metastasis via the complex N-glycosylation" 2018 *Oncogene*.
23. Chin, Y.T., Wang, L.M., Hsieh, M.T., Shih, Y.J., Nana, A.W., **Changou, C.A.**, Yang, Y.S.H., Chiu, H.C., Fu, E., Davis, P.J., Tang, H.Y., Lin, H.Y. "Leptin QB3 peptide suppresses leptin-induced signaling and progression in ovarian cancer cells" 2017 *J Biomed Sci*.
24. Shih, J.W., Chiang, W.F., Wu, A.T.H., Wu, M.H., Wang, L.Y., Yu, Y.L., Hung, Y.W., Wang, W.C., Chu, C.Y., Hung, C.L., **Changou, C.A.**, Yen, Y., Kung, H.J. "Long noncoding RNA LncHIFCAR/MIR31HG is a HIF-1 α co-activator driving oral cancer progression" 2017 *Nat Commun*.
25. Yu, J., Lee, C.Y., **Changou, C.A.**, Cedano-Prieto, D.M., Takada, Y.K., Takada, Y. "The CD9, CD81, and CD151 EC2 domain bind to the classical RGD-binding site of integrin $\alpha\upsilon\beta 3$ " 2017 *Biochem*.
26. Chou, S.Y., Ajoy, R., **Changou, C.A.**, Hsieh, Y.T., Wang, Y.K., Hoffer, B. "CCL5/RANTES contributes to hypothalamic insulin signaling for systemic insulin responsiveness through CCR5" 2016 *Sci Rep*.
27. Hsieh, M.T., Wang, L.M., **Changou, C.A.**, Chin, Y.T., Yang, Y.S., Lai H.Y., Lee S.Y., Yang, Y.N., Whang-Peng, J., Liu, L.F., Lin, H.Y., Mousa, S.A., Davis, P.J. "Crosstalk between integrin $\alpha\upsilon\beta 3$ and Er α contributes to thyroid hormone-induced proliferation of ovarian cancer cells" 2016 *Oncotarget*.
28. Lee, J.C., Su, S.Y., **Changou, C.A.**, Yang, R.S., Tsai, K.S., Collins, M.T., Orwoll, E.S., Lin, C.Y., Chen, S.H., Shih, S.R., Lee, C.H., Oda, Y., Billings, S.D., Li, C.F., Nielsen, G.P., Konishi, E., Petersson, F., Charpenter, T.O., Sittampalam, K., Huang, H.Y., and Folpe A.L. "Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors" 2016 *Mod Pathol*.
29. Lee, J.C., Lu, T.P., **Changou, C.A.**, Liang, C.W., Huang, H.N., Lauria, A., Huang, H.Y., Lin, C.Y., Chiang, Y.C., Davidson, B., Lin, M.C., and Kuo, K.T. "Genomewide copy number analysis of Mullerian adenosarcoma identified chromosomal instability in the aggressive subgroup" 2016 *Mod Pathol* (9):1070-82.
30. Kuo, M.L., Lee, M.B., Tang, M., den Besten W., Hu, S., Sweredoski, M.J., Hess, S., Chou, C.M., **Changou, C.A.**, Su, M., Jia, W., Su, L., Yen Y. "PYCR1 and PYCR2 interact and collaborate with RRM2B to protect cells from overt oxidative stress" 2016 *Sci Rep* (6):18846
31. Yang, S.H., Lin, H.Y., **Changou, C.A.**, Chen, C.H., Liu, Y.R., Wang, J., Jiang, X., Luh, F., Yen, Y. "Integrin $\beta 3$ and LKB1 are independently involved in the inhibition of proliferation by lovastatin in human intrahepatic cholangiocarcinoma" 2016 *Oncotarget*.
32. Chin, Y.T., Yang, S.H., Chang, T.C., **Changou C.A.**, Lai, H.Y., Fu, E., HuangFu, W.C., Davis P.J., Lin, H.Y., and Liu, L.F. 2015 *Oncotarget* (34): 25866-79.
33. Kung H.J.*, **Changou C.A.***, Li, C.F., and Ann, D.K. "Chromatophagy: Autophagy goes nuclear and captures broken chromatin during arginine-starvation". 2015 *Autophagy* (2): 419-21.

34. Guo, W., Liu, R., Bhardwaj, G., Yang, J.C., **Changou, C.A.**, Ma, A.H., Mazloom, A., Chintapalli S., Xiao K., Xiao W., Kumaresan, P., Sanchez, E., Yeh C.T., Evans C.P., Patterson, R., Lam K.S., Kung H.J. "Targetting Btk/Etk of prostate cancer cells by a novel dual inhibitor" 2014 Cell Death Dis.
35. **Changou, C.A.**, Chen, Y.R., Xing, L., Bold, R.J., Chuang, F.Y.S., Yun, Y., Cheng, R.H., Ann, D.K., Kung, H.J. "Arginine starvation induces atypical cellular death involving mitochondrial dysfunction, nuclear DNA leakage, and chromatin autophagy" 2014 Proc Natl Acad Sci USA 111(39):14147-52.
36. Kung, H.J., **Changou, C.A.**, Ngyuen, H., Yang, J.C., Evans, C., Bold, R., and Chuang F. "Autophagy and prostate cancer therapeutics" Prostate cancer: biochemistry, molecular biology and genetics 2013 (in press).
37. Guo, W., Liu R., Bhardwaj, G., Ma, A.H., **Changou, C.A.**, Yang, J.C., Li, Y., Feng, C., Luo, Y., Mazloom, A., Sanchez, E., Wang, Y., Huang, W., Patterson, R., Evans, C.P., Lam, K.S., and Kung, H.J. "CTA095, a novel Etk and Src dual inhibitor, induces apoptosis in prostate cancer cells and overcomes resistance to Src inhibitors" 2013. PLoS One. 8(8).
38. **Changou, C.A.**, Wolfson, D.L., Ahluwalia, B., Bold, R., Kung, H.J., Chuang, F. "Quantitative analysis of autophagy using advanced 3D fluorescence microscopy" 2013. J. Vis Exp. 3(75).
39. Salomoni, P., Bernadi, R., Bergmann, S., **Changou, A.**, Tuttle, S., and Pandolfi, PP. "The promyelocytic leukemia protein PML regulates c-Jun function in response to DNA damage." 2005. Blood. 105(9): 3686-90.
40. Best, J., Ganiatsas, S., Agarwal, S., **Changou, A.**, Shirihi, O., Meluh, PB., Pandolfi, PP., and Zon, LI. "SUMO-1 protease-1 regulates gene transcription through PML" 2002. Mol. Cell. 10(4): 843-55.

Speaker: Chun Austin Changou

Name: Shian-Ying Sung

Current Position:

2013 – present Associate Professor, Taipei Medical University

2018 – present Director, JCRC, Taipei Medical University

Educations:

2000 Ph.D. in Microbiol. & Immunol., Virginia Commonwealth Univ., Richmond, Virginia

Professional Experiences:

- 2019- Current Vice Dean, Office of Human Research, Taipei Medical University, Taipei Taiwan
- 2015 – 2019 Deputy Director, Join Clinical Research Center, Office of Human Research, Taipei Medical University, Taipei Taiwan
- 2012-2013 Associate Professor, Grad. Inst. Of Cancer Biol. China Medical Univ. School of Medicine, Taichung, Taiwan
- 2007 – 2013 Assistant Professor, Grad. Inst. of Cancer Biol., China Medical Univ. School of Medicine, Taichung, Taiwan
- 2006 – 2007 Instructor, Depts. of Urology & Radiation Oncology, Emory University School of Medicine, Atlanta, GA, USA

Selected Publications: (most recent 10 publications)


1. Do AD, Kurniawati I, Hsieh CL, Wong TT, Lin YL, Sung SY. Application of Mesenchymal Stem Cells in Targeted Delivery to the Brain: Potential and Challenges of the Extracellular Vesicle-Based Approach for Brain Tumor Treatment. **Int. J. Mol. Sci.** **2021 Oct. 17**; 22(20): 11187
2. Huang SS, Liao WY, Hsu CC, Chan TS, Liao TY, Yang PM, Chen LT, Sung SY, Tsai KK. A novel invadopodia-specific marker for invasive and pro-metastatic cancer stem cells. **Frontier in Oncology**, **2021 May 31**; 11: 718849.
3. Su CM, Hsu TW, Sung SY, Huang MT, Chen KC, Huang CY, Chiang CY, Su YH, Chen HA, Liao PH. AXL is crucial for E1A-enhanced therapeutic efficiency of EGFR tyrosine kinase inhibitors through NFI in breast cancer. **Environ. Toxicol.** **2021 Mar 18**; 36(7): 1278-1287
4. Chen BW, Chiu GW, He YC, Huang CY, Huang HT, Sung SY, Hsieh CL, Chang WC, Hsu MS, Wei ZH, Yao DJ. Extracellular and intracellular intermittent magnetic-fluid hyperthermia treatment of SK-Hep1 hepatocellular carcinoma cells based on magnetic nanoparticles coated with polystyrene sulfonic acid. **PLoS One** **2021 Feb 5**; 16(2): e0245286.
5. Shigemura K, Sung SY, Fujisawa M. et al., Effect of Preoperative Dutasteride on Holmium Laser Enucleation of the Prostate. **Urol. Int.** **2020 Sep**; **104(5-6): 356-360.**
6. Chen BW, He YC, Sung SY, Yao DJ et al., Synthesis and characterization of magnetic nanoparticles coated with polystyrene sulfonic acid for biomedical applications. **Sci Technol Adv. Mater.** **2020 Jul 22**; **21(1): 471-481.**

7. Ishii A, Shigemura K, Sung SY, Fujisawa M et al., Anti-tumor Effect of Hedgehog Signaling Inhibitor, Vismodegib, on Castration-resistant Prostate Cancer. **Anticancer Res.**, 2020 Sep; 40(9): 5107-5114.
8. Yi-Te C., Sung SY, Fujisawa M et al., Urinary tract infection pathogens and antimicrobial susceptibilities in Kobe, Japan and Taipei, Taiwan: an international analysis. **J. Int. Med. Res.** 2020 Feb; 48(2): 300060519867826
9. Tran HM, Wu KS, Sung SY, Wong TT et al., Upregulation of Protein Synthesis and Proteasome Degradation Confers Sensitivity to Proteasome Inhibitor Bortezomib in Myc-Atypical Teratoid/Rhabdoid Tumors. **Cancers (Basel).** 2020 Mar 22; 12(3):752.
10. Wu KS, Sung SY, Wong TT et al., Molecular-Clinical Correlation in Pediatric Medulloblastoma: A Cohort Series Study of 52 Cases in Taiwan. **Cancers (Basel).** 2020 Mar 11; 12(3):653.

Topic: TMU Biobank for the preclinical research, clinical translation and Precision Medicine

Speaker: Shian-Ying Sung

CURRICURUM VITAE



Full Name: Jowy Tani

Dr. Jowy Tani is the founder and CEO of Taipei Medical University Biomed Accelerator. As a Stanford Biodesign Global Faculty and a Berkeley-Taiwan Biomedical Scholar, he has extensive experience in leading medical innovation projects, coaching Medtech strategies for startups, Medtech investment analysis, as well as forming a biomedical innovation ecosystem. A physician-scientist specializing in neurology, Dr. Tani has in-depth expertise in dementia, neurocritical care, and electroneurophysiology. He is also currently serving as the Deputy Secretary-General of Taiwan Neurological Society, Deputy Director of Wan Fang Hospital Biomedical Innovation Center, and Deputy Director of TMU Biodesign Center.



Topic: Accelerating biomedical innovation with a strong clinical strategy

Speaker: Jowy Tani

CURRICURUM VITAE



Full Name: Arthur Chen

Managing Partner at BE Health Ventures

A serial entrepreneur and venture capitalist, Arthur works as the Managing Partner at BE Health Ventures, a healthcare focused investment firm, where he manages and invests a portfolio of medical technology ventures in the USA, Euro, and Asia.

Arthur's passion is to empower young entrepreneurs. He is a startup venture builder at universities to help grow student teams from idea stages to real enterprises, a member of the board at Taiwan Startup Stadium (one of the largest startup incubation hubs in Asia) to coach Taiwan startups to go global and rock the world, and an impact investor at #43 Ventures to support social enterprises that make our world better.

Experience:

Company Name : BE Health (比翼生醫)

Total Duration: 5 yrs

Title : Managing Partner (執行合夥人) at BE Health Ventures

Dates Employed : May 2019 – Present

Employment Duration: 2 yrs 6 mos

BE Health Ventures is accelerator VC and venture builder. We back startups that are looking to make impact for the next 10 years and beyond.

Title Executive Director (執行董事) at BE Capital

Dates Employed 2016 – Present

Employment Duration: 5 yrs

Location Greater China and USA

BE Capital is a healthcare focused investment firm formed making investments into promising private and public hospital and healthcare technology ventures in the Greater China and USA.

Topic: How VC and Accelerator Help Startups Hit New Heights

Speaker: Arthur Chen



THE
REACTA FORUM
REACTA and TMU Clinical Trial Alliance International Conference



臺北醫學大學
TAIPEI MEDICAL UNIVERSITY

See you next year!

www.reacta.com.tw

Regional Asian Clinical Trial Association